EP1556375B1 - Flavon derivate als inhibitoren von cyclin-abhängigen kinasen - Google Patents

Flavon derivate als inhibitoren von cyclin-abhängigen kinasen Download PDF

Info

Publication number
EP1556375B1
EP1556375B1 EP03753911A EP03753911A EP1556375B1 EP 1556375 B1 EP1556375 B1 EP 1556375B1 EP 03753911 A EP03753911 A EP 03753911A EP 03753911 A EP03753911 A EP 03753911A EP 1556375 B1 EP1556375 B1 EP 1556375B1
Authority
EP
European Patent Office
Prior art keywords
trans
chromen
hydroxymethyl
phenyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP03753911A
Other languages
English (en)
French (fr)
Other versions
EP1556375A2 (de
Inventor
Bansi Lal
Kalpana Sanjay Joshi
Sanjeev Anant Kulkarni
Malcolm Mascarenhas
Shrikant Gangadhar Kamble
Maggie Joyce 201/A Nirmal Co-op Hsg So. RATHOS
Rajendrakumar Dinanath Joshi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Piramal Enterprises Ltd
Original Assignee
Nicholas Piramal India Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicholas Piramal India Ltd filed Critical Nicholas Piramal India Ltd
Publication of EP1556375A2 publication Critical patent/EP1556375A2/de
Application granted granted Critical
Publication of EP1556375B1 publication Critical patent/EP1556375B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Definitions

  • the present invention relates to novel inhibitors of cyclin-dependent kinases (CDKs), to processes for their preparation, their use as active ingredients in pharmaceuticals, in particular for the treatment of proliferative disorders, and to pharmaceutical preparations comprising them.
  • CDKs cyclin-dependent kinases
  • the ability of eukaryotic cells to proliferate in response to a growth signal is tightly controlled by a complex network of ordered biochemical events collectively known as the cell cycle.
  • Mitogenic signals commit cells to entry into a series of regulated steps of the cell cycle.
  • the synthesis of DNA (S phase), and separation of two daughter cells (M phase) are the main features of cell cycle progression.
  • the G1 phase separates the M and S phases and prepares the cell for DNA duplication upon receiving mitogenic signals.
  • the period between the S and M phases is known as the G2 phase during which cells repair errors that occurred during DNA duplication.
  • CDKs Cyclin-dependent kinases
  • CDKs consist of a catalytic subunit (the actual cyclin-dependent kinase or CDK) and a regulatory subunit (cyclin).
  • CDKs There are at least nine CDKs (CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, etc.) and 15 different types of cyclins (cyclin A, B1, B2, D1, D2, D3, E etc.).
  • CDK complexes G1/S transition (CDK2/cyclin A, CDK4/cyclin D1-D3, CDK6/cyclin D3) ( Senderwicz A.M. and Sausville E.A., J Natl. Cancer Inst. 2000, 376-387 ), S phase (CDK2/cyclin A), G2 phase (CDK1/cyclin A), G2/M transition phase (CDK1/cyclins B).
  • CDKs are able to phosphorylate many proteins that are involved in cell cycle events, including tumor suppressor proteins, such as the retinoblastoma gene product Rb.
  • the Rb is involved in the G1/S transition of the cell cycle and its phosphorylation by CDKs results in its inactivation ( US-A-5 723 313 ), which in turn leads to the release of the transcriptional factor E2F and the activation of E2F-responsive genes necessary for progression to the S phase.
  • CDKs A wide variety of diseases are characterized by uncontrolled cell proliferation that results from some fault in the regulatory pathways in the cell cycle [e.g. overexpression of cyclins or deletions of genes encoding CKIs (CDK inhibitory proteins)].
  • the overexpression of cyclinD1 leads to the deregulation of CDK4-D1 kinase activity and thereby contributes to uncontrolled cell proliferation.
  • CDKs are attractive targets for the development of anti-tumor drugs.
  • the first potent molecule to be developed as an effective CDK inhibitor was a flavone compound, namely flavopiridol [ cis - ⁇ 2-(2-Chloro-phenyl)-5,7-dihydroxy-8-(3-hydroxy-1-methyl-piperidin-4-yl)-chromen-4-one hydrochloride ⁇ ].
  • Flavopiridol is known to inhibit different CDKs and it exhibits anti-proliferative activity in vitro against a broad range of human cancer cells. Further research on flavones as a class of compounds offers a potential approach to anti-proliferative therapy. As a result, analogs of flavopiridol have been the subject of other publications.
  • US-A-5 733 920 describes novel chromone analogs as inhibitors of CDK/Cyclin complexes.
  • US-A-5 849 733 discloses 2-thio and 2-oxo analogs of flavopiridol as protein kinase inhibitors for the treatment of proliferative diseases.
  • WO 01/83469 discloses 3-hydroxychromen-4-one derivatives as inhibitors of cyclin dependent kinases.
  • US-A-5 116 954 and US H1427 disclose flavonoid compounds having anticancer and immunomodulatory activity.
  • US-A-5 284 856 discloses use of benzopyran-4-one derivatives for the control of tumoral diseases.
  • US-A-4 900 727 discloses benzopyran-4-one derivatives antiinflammatory agents. Anti-inflammatory benzopyran-4-one derivative from Dysoxylum binectariferum is described by R.G.Naik et al in Tetrahedron, 1988, 44 (7), 2081-2086 .
  • CDK/cyclin kinase complexes in particular CDK4/cyclin D kinase complexes, in the induction of cell proliferation and their deregulation in tumors, makes them ideal targets for developing highly specific anti-proliferative agents.
  • CDK inhibitors which can be used as anti-proliferative agents in an efficient or more specific manner.
  • a focused research on CDK inhibitors by the present inventors resulted in the discovery of novel flavone analogs possessing structural features not envisaged in the prior art, as effective inhibitors of CDKs.
  • the compounds of the invention inhibit CDKs effectively with greater selectivity than the known CDK inhibitors, which are under clinical trials (Curr.Pharm.Biotechnol. 2000, July (1): 107-116) and also show comparatively low cytotoxicity against various different proliferative cell lines. Therefore, the compounds of the present invention are candidate agents for the treatment of various cell proliferation related disorders.
  • the present invention generally relates to compounds of the general formula (Ic), a tautomeric form, stereoisomer, optical isomer, pharmaceutically acceptable salt, pharmaceutically acceptable solvate or polymorph thereof wherein
  • the present compounds are inhibitors of mammalian CDK/cyclin complexes, as well as inhibitors of insect CDK, plant CDK and of fungal CDK complexes.
  • the present compounds are inhibitors of the kinase activity of CDK/cyclin complexes, e.g. the CDK2/cyclin E and CDK4/cyclin D1 complexes.
  • the present invention further relates to processes for the preparation of compounds of formula (Ic), use of the compounds as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
  • the pharmaceutical preparations can be used to inhibit excessive proliferation of a eukaryotic cell, e.g., a mammalian cell, an insect cell, a plant cell, and/or a fungal cell, and/or prevent dedifferentiation of such cells.
  • a eukaryotic cell e.g., a mammalian cell, an insect cell, a plant cell, and/or a fungal cell, and/or prevent dedifferentiation of such cells.
  • the present compounds can be used in the treatment of proliferative disorders in mammals, especially humans, marked by unwanted proliferation of endogenous tissue.
  • the present compounds are inhibitors of CDKs, particularly CDK/cyclin complexes and find use in antiproliferative therapies for diseases characterized by excessive cell growth such as cancers, cardiovascular abnormalities, nephrological disorders, psoriasis, Alzheimer's disease, immunological disorders involving unwanted proliferation of leukocytes, restenosis and other proliferative smooth muscle disorders, viral infections, and mycotic infections.
  • flavone means compounds that can be represented by the following basic structure: wherein Z may represent an oxygen atom, a sulfur atom or NR 8 (where R 8 is defined as hereinabove).
  • alkyl refers to the radical of saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. Furthermore, unless stated otherwise, the term “alkyl” includes unsubstituted alkyl groups as well as alkyl groups, which are substituted by one or more different substituents.
  • a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C 1 -C 30 for straight chain, C 3 -C 30 for branched chain), and more preferably 20 or fewer.
  • preferred cycloalkyls have from 3-10 carbon atoms in their ring structure, and more preferably have 5, 6 or 7 carbons in the ring structure.
  • alkyl residues containing from 1 to 20 carbon atoms are: methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tetradecyl, hexadecyl, octadecyl and eicosyl, the n-isomers of all these residues, isopropyl, isobutyl, 1-methylbutyl, isopentyl, neopentyl, 2,2-dimethylbutyl, 2-methylpentyl, 3-methylpentyl, isohexyl, 2,3,4-trimethylhexyl, isodecyl, sec-butyl, or tert-butyl.
  • alkyl residues containing 3, 4, 5, 6 or 7 ring carbon atoms are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl which can also be substituted.
  • alkyl as used herein also comprises cycloalkyl-substituted alkyl groups and alkyl-substituted cycloalkyl groups.
  • cycloalkyl-substituted alkyl groups are: cyclopropylmethyl-, cyclobutylmethyl-, cyclopentylmethyl-, cyclohexylmethyl-, cycloheptylmethyl-, 1-cyclopropylethyl-, 1-cyclobutylethyl-, 1-cyclopentylethyl-, 1-cyclohexylethyl-, 1-cycloheptylethyl-, 2-cyclopropylethyl-, 2-cyclobutylethyl-, 2-cyclopentylethyl-, 2-cyclohexylethyl-, 2-cycloheptylethyl-, 3-cyclopropylpropyl-, 3-cyclobutylpropyl-, 3-cyclopentylpropyl-, 3-cyclohexylpropyl-, 3-cycloheptylpropyl-, etc. in which groups the cycloalkyl group as well as
  • a cyclic alkyl group has to contain at least three carbon atoms.
  • a group like (C 1 -C 8 )-alkyl is to be understood as comprising, among others, saturated acyclic (C 1 -C 8 )-alkyl, (C 3 -C 8 )-cycloalkyl, alkyl-cycloalkyl groups or cycloalkyl-alkyl groups like (C 3 -C 7 )-cycloalkyl-(C 1 -C 3 )-alkyl-, wherein the total number of carbon atoms can range from 4 to 8.
  • a group like (C 1 -C 4 )-alkyl is to be understood as comprising, among others, saturated acyclic (C 1 -C 4 )-alkyl, (C 3 -C 4 )-cycloalkyl, cyclopropyl-methyl- or methyl-cyclopropyl-.
  • alkyl preferably comprises acyclic saturated hydrocarbon residues which have from 1 to 6 carbon atoms and which can be linear or branched, and cyclic alkyl groups containing from 3 to 8 ring carbon atoms, in particular from 3 to 6 ring carbon atoms.
  • a particular group of saturated acyclic alkyl residues is formed by (C 1 -C 4 )-alkyl residues like methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl.
  • alkyl groups can in general be unsubstituted or substituted by one or more, for example 1, 2, 3, 4 or 5 identical or different substituents, Any kind of substituents present in substituted alkyl residues can be present in any desired position provided that the substitution does not lead to an unstable molecule.
  • a substituted alkyl refers to an alkyl residue in which one or more, for example, 1, 2, 3, 4 or 5, hydrogen atoms are replaced with substituents, for example, halogen, hydroxyl, carbonyl, alkoxyl, ester, ether, cyano, amino, amido, imino, sulfhydryl, alkylthio, thioester, sulfonyl, nitro, azido, acyloxy, heterocyclo, aralkyl, or an aryl or heteroaryl group.
  • the carbon backbone of the alkyl group may be interrupted by heteroatoms such as oxygen, sulfur or nitrogen.
  • substituted acyclic alkyls are hydroxymethyl, hydroxyethyl, 2-hydroxyethyl, aminoethyl or morpholinoethyl.
  • substituted cycloalkyl groups are cycloalkyl groups which carry as substituent one or more, for example 1, 2, 3, 4 or 5, identical or different acyclic alkyl groups, for example acyclic (C 1 -C 4 )-alkyl groups like methyl groups.
  • substituted cycloalkyl groups are 4-methylcyclohexyl, 4-tert-butylcyclohexyl or 2,3-dimethylcyclopentyl.
  • the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate.
  • the substituents of a substituted alkyl may include substituted and unsubstituted forms of amino, imino, amido, sulfonyl (including sulfonate and sulfonamide), as well as ether, alkylthio, carbonyl (including ketones, aldehydes, carboxylates; and esters), -CF 3 , -CN and the like.
  • Cycloalkyls can be further substituted with alkyl, alkenyl, alkoxyl, alkylthio, aminoalkyls, carbonyl-substituted alkyl, -CF 3 , cyano (CN), and the like.
  • alkoxyl or "alkoxy” as used herein refers to an alkyl group, as defined above, having an oxygen radical attached thereto.
  • Representative alkoxyl groups include methoxy, ethoxy, propoxy, tert-butoxy and the like.
  • aralkyl refers to an alkyl group, as defined above, substituted with an aryl or heteroaryl group (defined below).
  • exemplary aralkyl groups include benzyl, -(CH 2 )-pyridyl, etc.
  • alkenyl and alkynyl refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond, respectively, for example 1, 2 or 3 double bonds and/or triple bonds, provided that the double bonds are not located within a cyclic alkyl group in such a manner that an aromatic system results.
  • alkenyl groups include vinyl, 1-propenyl, 2-propenyl, 2-butenyl, 2-methyl-1-propenyl or 3-methyl-2-butenyl.
  • alkynyl groups include ethynyl, 2-propynyl, 2-butynyl or 3-butynyl. Alkyl groups can also be unsaturated when they are substituted.
  • alkenyl and alkynyl include unsubstituted alkenyl and alkynyl groups as well as alkenyl and alkynyl groups which are substituted by one or more, for example 1, 2, 3, 4 or 5, identical or different groups mentioned above for alkyl, for example, aminoalkenyl, aminoalkynyl, amidoalkenyl, amidoalkynyl, iminoalkenyl, iminoalkynyl, thioalkenyl, thioalkynyl, carbonyl-substituted alkenyl or alkynyl, alkenoxyl or alkynoxyl.
  • lower means that the group it is describing has up to 10 carbon atoms, more preferably up to 6 carbon atoms in its backbone structure.
  • lower alkenyl means an alkenyl group as defined above having 2 to 10 or, more preferably, 2 to 6 carbon atoms.
  • aryl refers to monocyclic or polycyclic hydrocarbon groups having up to 14 ring carbon atoms in which at least one carbocyclic ring is present that has a conjugated pi electron system.
  • Examples of (C 6 -C 14 )-aryl residues are phenyl, naphthyl; biphenyl, fluorenyl or anthracenyl.
  • Examples of (C 6 -C 10 )-aryl residues are phenyl or naphthyl.
  • aryl residues for example phenyl, naphthyl or fluorenyl, can in general be unsubstituted or substituted by one or more, for example 1, 2, 3, 4 or 5, identical or different substituents.
  • substituents that can be present in substituted aryl groups are: F, Cl, Br, I, alkyl, alkenyl, alkynyl, CF 3 , hydroxyl, aryloxy, amino, cyano, nitro, thiol, imine, amide or carbonyl (such as carboxyl, formate, carbamide, an ester, ketone or aldehyde), sulfhydryl, silyl ether, thiocarbonyl (such as thioester, thioacetate or thioformate), sulfonyl, aminoacid ester, or a heterocyclo group which is saturated, partially unsaturated or aromatic.
  • Aryl residues can be bonded via any desired position, and in substituted aryl residues the substituents can be located in any desired position.
  • the substituent in monosubstituted phenyl residues the substituent can be located in the 2- position, the 3-position, the 4-position or the 5-position, with the 2-position being preferred. If the phenyl group carries two substituents, they can be located in 2,3-position, 2,4-position, 2,5-position, 2,6-position, 3,4-position or 3,5-position.
  • heterocycle and “heterocyclo” refer to a saturated, partially unsaturated or aromatic monocyclic or polycyclic heterocyclic ring system containing 3, 4, 5, 6, 7, 8, 9,10, 11, 12, 13 or 14 ring atoms of which 1, 2, 3 or 4 are identical or different heteroatoms selected from the series consisting of nitrogen, oxygen, sulfur and phosphorus.
  • the heterocyclo group may, for example, have 1 or 2 oxygen atoms and /or 1 or 2 sulfur atoms, 1 to 4 nitrogen atoms and/or 1 or 2 phosphorus atoms in the ring.
  • heterocyclo preferably is a 3-membered, 4-membered, 5-membered, 6-membered or 7-membered ring, particularly preferably a 5-membered or 6-membered ring.
  • heterocyclo groups are piperazinyl and piperidinyl.
  • heterocyclo may comprise either fused rings in which two or more carbons are common to two adjoining rings, or bridged rings in which rings are joined through non-adjacent atoms.
  • heterocyclo preferably comprises two fused rings (bicyclic) one of which is a 5-membered or 6-membered heterocyclic ring and the other of which is a 5-membered or 6-membered heterocyclic ring.
  • bicyclic and tricyclic heterocyclic groups include benzoxazolyl, quinolyl, isoquinolyl, carbazolyl, indolyl, isoindolyl, phenoxazinyl, benzothiazolyl, benzimidazolyl, benzoxadiazolyl and benzofurazanyl.
  • the ring heteroatoms can be present in any desired number and in any position with respect to each other provided that the resulting heterocyclic system is known in the art and is stable and suitable as a subgroup in a drug substance.
  • heterocyclo groups examples include: pyrrolyl, furyl, thiophen-yl, imidazolyl, oxazolyl, isoxazolyl thiazolyl, isothiazolyl triazolyl, pyrazolyl, pyridinyl, pyrazinyl, pyridazinyl; pyrimidinyl, azepinyl, tetrahydrothiophen-yl, tatrahydrofuran-yl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, lactams, pyrrolidinyl, azetidinyl.
  • the heterocyclo group may be bonded via any ring carbon atom, and in the case of nitrogen heterocycles via any suitable ring nitrogen atom.
  • a pyrrolyl residue can be 1-pyrrolyl, 2-pyrrolyl or 3-pyrrolyl
  • imidazolyl can be 1- imidazolyl, 2-imidazolyl, 4-imidazolyl or 5-imidazolyl.
  • R 9 and R 10 may, together with the nitrogen atom to which they are attached form a heterocyclic ring having one or more heteroatoms.
  • Suitable examples of heterocyclic rings formed by R 9 and R 10 , together with the nitrogen to which they are attached, are piperidine, pyrrolidine, morpholine, piperazinyl or imidazole, which can be unsubstituted or substituted as indicated below.
  • Heterocyclo comprises saturated heterocyclic ring systems which do not contain any double bonds within the rings, as well as mono-unsaturated and polyunsaturated heterocyclic ring systems which contain one or more, for example 1, 2, 3, 4 or 5, double bonds within the rings provided that the resulting system is stable.
  • Unsaturated rings may be non-aromatic or aromatic.
  • Aromatic heterocyclo groups may also be referred to by the customary term "heteroaryl" for which all the definitions and explanations above and below relating to heterocyclo apply.
  • the heterocyclo group can be unsubstituted or substituted on ring carbon atoms with one or more, for example 1, 2, 3, 4 or 5 identical or different substituents.
  • Each suitable ring nitrogen atom in a heterocyclo group can independently of each other be unsubstituted, i.e. carry a hydrogen atom, or can be substituted.
  • substituents for the ring carbon and ring nitrogen atoms are: (C 1 -C 8 )-alkyl, in particular (C 1 -C 4 )-alkyl, alkoxy, halogen, hydroxyl, hydroxy-(C 1 -C 4 )-alkyl such as, for example, hydroxymethyl or 1-hydroxyethyl or 2-hydroxyethyl, alkenyl, alkynyl, CF 3 , aryloxy, amino, cyano, nitro, thiol, imine, amide or carbonyl (such as carboxyl, formate, carbamide, an ester, ketone or aldehyde), silyl ether, thiocarbonyl (such as thioesters, a thioacetate or a thioformate), sulfonyl, aminoacid ester, heterocyclo, aryl or the like.
  • the substituents can be present at one or more positions provided that a stable molecule results
  • heteroatom as used herein means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, sulfur and phosphorous.
  • Halogen is fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or bromine.
  • substitution or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, as well as represents a stable compound, which does not readily undergo transformation such as by rearrangement, cyclization, elimination, etc.
  • any heteroatom with unsatisfied valences is assumed to have the hydrogen atom to satisfy the valences.
  • Specific inhibitors or “specific inhibition” implies the selectivity of the drug for its inhibitory effect towards a particular CDK-cyclin complex.
  • Certain compounds of the present invention may exist in particular geometric or stereoisomeric forms. Centers of asymmetry that are present in the compounds of formula (Ic) all independently of one another have S configuration or R configuration.
  • the present invention includes all possible enantiomers and diastereomers in pure or substantially pure form and mixtures of two or more stereoisomers, for example mixtures of enantiomers and/or diastereomers, in all ratios.
  • compounds according to the present invention which can exist as enantiomers can be present in enantiomerically pure form, both as levorotatory and as dextrorotatory antipodes, in the form of racemates and in the form of mixtures of the two enantiomers in all ratios.
  • the invention includes both the cis form and the trans form as well as mixtures of these forms in all ratios.
  • the preparation of individual stereoisomers can be carried out, if desired, by separation of a mixture by customary methods.
  • the racemic forms can be resolved by physical methods, such as fractional crystallization or separation by chiral column chromatography.
  • the individual optical isomers can be synthesized in the optically pure form by the use of enzymes or through asymmetric synthesis.
  • a particular enantiomer of a compound of the present invention may be prepared by derivatization with a chiral auxiliary whereby the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomer.
  • the compound contains a basic functional group such as an amino or an acidic functional group such as a carboxyl
  • diastereomeric salts are formed by reacting the compound with an appropriate optically active acid or base, respectively.
  • the diastereomeric salts thus formed are separated by fractional crystallization or chromatographic means well known in the art and the pure enantiomers are subsequently isolated from the diastereomeric salts.
  • the separation of a mixture of stereoisomers can be carried out at the stage of the compounds of formula (Ic) or at the stage of an intermediate during the synthesis.
  • the present invention also includes all tautomeric forms of the compounds of formula (Ic). Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.
  • the invention also comprises their corresponding pharmaceutically or toxicologically acceptable salts, in particular their pharmaceutically utilizable salts.
  • Compounds of formula (Ic) which contain one or more basic groups, i.e. groups which can be protonated, can be present and can be used according to the invention in the form of their addition salts with non-toxic inorganic or organic acids.
  • suitable inorganic acids include: boric acid, perchloric acid, hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid, nitric acid and other inorganic acids known to the person skilled in the art.
  • Suitable organic acids include: acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, pamoic acid, maleic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, sulfanilic acid, 2-acetoxybenzoic acid, fumaric acid, toluenesulfonic acid, methanesulfonic acid, ethane disulfonic acid, oxalic acid, isethionic acid, ketoglutaric acid, benzenesulfonic acid, glycerophosphoric acid and other organic acids known to the person skilled in the art.
  • the compounds of formula (Ic) which contain acidic groups can be used according to the invention, for example, as alkali metal salts like Li, Na, and K salts, as alkaline earth metal salts like Ca, Mg salts, as aluminium salts, as salts of organic bases such as lysine, arginine, guanidine, diethanolamine, choline, tromethamine, or as salts with ammonia.
  • alkali metal salts like Li, Na, and K salts
  • alkaline earth metal salts like Ca
  • Mg salts as aluminium salts
  • organic bases such as lysine, arginine, guanidine, diethanolamine, choline, tromethamine, or as salts with ammonia.
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the subject compound which contains a basic or acidic moiety by conventional chemical methods.
  • the salts are prepared by contacting the free base or acid with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid or base in a suitable solvent or dispersant or by anion exchange or cation exchange with other salts.
  • Suitable solvents are, for example, ethyl acetate, ether, alcohols, acetone, THF, dioxane or mixtures of these solvents.
  • the present invention furthermore includes all solvates of compounds of formula (Ic), for example hydrates or adducts with alcohols.
  • polymorphs of compounds of general formula (Ic) forming part of this invention may be prepared by crystallization of compounds of formula (Ic) under different conditions. For example, using different commonly used solvents or their mixtures for crystallization; crystallization at different temperatures; various modes of cooling, ranging from very fast to very slow cooling during crystallizations. Polymorphs may also be obtained by heating or melting the compound followed by gradual or fast cooling. The presence of polymorphs may be determined by IR spectroscopy, solid probe NMR spectroscopy, differential scanning calorimetry, powder X-ray diffraction or such other techniques.
  • Preferred compounds are those in which one or more of the groups contained therein have the meanings given below, with all the combinations of preferred substituent definitions being a subject of the present invention.
  • the present invention also includes all stereoisomeric forms and mixtures thereof in all ratios and their pharmaceutically acceptable salts.
  • A is a 5-membered saturated or unsaturated ring represented by any one of the general structures (i) to (iv); wherein X 1 is either a carbon atom or a heteroatom selected from: oxygen, sulfur, and nitrogen, except that in structure (iv) X 1 is either a carbon atom or a nitrogen atom; and R 6 and R 13 are as defined above.
  • R 1 is phenyl, which is unsubstituted or substituted by 1, 2, or 3 identical or different substituents selected from: halogen, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, nitro, NR 9 R 10 , SR 11 , trifluoromethyl, hydroxyl, cyano, carboxy, C 1 -C 4 -alkoxycarbonyl and -C 1 -C 4 -alkylenehydroxyl, or is a heterocycle, which is a saturated, partially unsaturated or aromatic ring containing 6 ring atoms of which 1, 2 or 3 are identical or different heteroatoms selected from: nitrogen, oxygen and sulfur, and where the heterocycle is unsubstituted or substituted by 1, 2, or 3 identical or different substituents selected from: halogen, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, nitro, NR 9 R
  • the present invention relates to compounds of the general formula (Ic), wherein R 1 is phenyl or pyridinyl, substituted by 1, 2 or 3 identical or different substituents selected from: halogen and nitro, R 2 and R 4 are hydrogen, R 3 and R 5 are hydroxyl, A is a saturated 5-membered ring represented by any one of the general structures (i) to (v), wherein X 1 , X 2 , R 6 and R 13 are as defined. More particularly, X 1 is carbon, X 2 is nitrogen, R 6 is -C 1 -C 4 -alkylenehydroxyl, R 13 is C 1 -C 4 -alkyl and Z is an oxygen atom.
  • A can be a saturated or unsaturated 5-membered ring containing at least one heteroatom selected from: nitrogen, oxygen and sulfur, the ring being unsubstituted or at least monosubstituted by R 6 .
  • the unsaturated 5-membered ring can have one or two double bonds in its ring structure.
  • A can in particular be a saturated 5-membered ring containing 1 or 2 nitrogen atoms, and in formula (Ic), wherein the ring is unsubstituted or at least monosubstituted by R 6.
  • A is a 5-membered ring of general structures (i) to (v) and both X 1 and X 2 independently represent a heteroatom selected from nitrogen, oxygen and sulfur, the following conditions apply:
  • the present invention also relates to processes for the preparation of compounds of formula (Ic) or pharmaceutically acceptable salts thereof.
  • One such process comprises reacting a benzopyranone of formula (II): wherein R 1 , R 2 , R 3 , R 4 , R 5 and Z have the meaning defined above and P is a functional group, with a compound of formula (III), wherein A is substituted by R 6 and R 7 , and A, R 6 and R 7 have the meaning defined above, except that A is other than a 5-membered ring of the general structure (ii) and (v) above, wherein X 1 is a nitrogen atom; Q is a functional group bound to a saturated or unsaturated carbon atom in the A ring, P and Q being capable of forming a carbon-carbon coupling between the respective carbon atoms to which they are attached, and
  • a compound of formula (Ic) or a pharmaceutically acceptable salt thereof can be prepared by reacting a compound of formula (XA): wherein in each case R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and A are as defined above, with an organic or inorganic base, subsequently adding an acid capable of effecting cyclization to the reaction mixture, followed by adding an an organic or inorganic base and, if appropriate, converting the resultant compound of formula (Ic) into a pharmaceutically acceptable salt, or reacting a compound of formula (XIIA); wherein in each case R 1 , R 2 , R 3 , R 4, R 5 , R 6 , R 7 and A are as defined above, with an acid capable of effecting cyclization, and then adding an organic or inorganic base to the reaction mixture, and, if appropriate, converting the resultant compound of formula (Ic) into a pharmaceutically acceptable salt.
  • Compound of formula (XIIA) is obtained from compound of formula (XIA) by treatment with an appropriate carboxylic acid ester such as R 1 COOMe, R 1 COOEt etc. or with an acid chloride like R 1 COX wherein X is a halogen or with an activated ester such as an anhydride in the presence of a base such as NaH in a solvent such as DMF, THF or 1,4-dioxane.
  • an appropriate carboxylic acid ester such as R 1 COOMe, R 1 COOEt etc.
  • A can be selected from:
  • R 11 can be hydrogen and/or R 13 can be methyl.
  • a process for the preparation of a compound of formula (XIILA) or a pharmaceutically acceptable salt thereof wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 13 and Z are as defined above comprises reacting a compound of formula (VIIA) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 13 and Z are as defined above, with a reagent suitable to effect replacement of the -OH group on the piperidino ring by a good leaving group, In the presence of an organic or inorganic base, followed by adding a suitable organic base in the presence of a suitable organic solvent to effect contraction of the piperidino ring and, if appropriate, converting the resultant compound of formula (XIIIA) into a pharmaceutically acceptable salt
  • a process for the preparation of a compound of formula (XXXIA) or a pharmaceutically acceptable salt thereof wherein R 1 , R 2 , R 3 , R 4 , R 5 and Z are as defined above comprises reacting a benzopyranone of formula (XXXA): wherein R 1 , R 2 , R 3 , R 4 , R 5 and Z are as defined above, with N-allyl N-chlorotosylamide in the presence of an alkylborane and, if appropriate, converting the resultant compound of formula (XXXIA) into a pharmaceutically acceptable salt.
  • a process for the preparation of a compound of formula (XXXVII): wherein R 1 , R 2 , R 3 , R 4 , R 5 and Z are as defined comprises reacting a compound of formula (XXXVI): wherein R 1 , R 2 , R 3 , R 4 , R 5 and Z are as defined above, with a suitable reducing agent capable of converting the ester group -C(O)OEt on the imidazolyl ring into the group -CH 2 OH and, if appropriate, converting the resultant compound of formula (XXXVII) into a pharmaceutically acceptable salt.
  • the compound of formula (XXXVI) above is prepared by reacting a compound of formula (XXXV): wherein R 1 , R 2 , R 3 , R 4, R 5 and Z are as defined, with an isocyanide in the presence of an inorganic base in an organic solvent.
  • the present invention also relates to a process for the resolution of a compound of general formula (VIII A) or a pharmaceutically acceptable salt thereof: wherein R 3 , R 4 , R 5 , R 6 and A are as defined, which process comprises reacting the racemic compound of formula (VIIIA) with a chiral auxiliary in the presence of a solvent, crystallising out the required diastereomeric salt and subsequently treating with base to obtain the desired enantiomer of the compound of formula (VIII A).
  • the compounds of the present invention are formed in scheme 1 by a metal catalyzed C-C bond coupling reaction well known in the art.
  • P is a functional group, for example, Li, a halogen such as Cl, Br or I, a triflate or p-fluorobenzenesulfonate.
  • A may be an optionally substituted 5-membered ring as defined above.
  • Q is attached to an unsaturated bond at position C 1 of ring A and is a halogen or a functionality suitable for coupling with the compound of formula (II) using organometallic catalysts.
  • Organometallic catalysts such as palladium complexes, for example, Pd(OAc) 2 , PdCl 2 (PhCN) 2 and Pd(Ph 3 P) 4 may be used for coupling. Coupling is earned out in presence of bases like sodium carbonate, potassium carbonate, piperidine and pyrrolidine, using solvents such as DMF. The double bond at position C 1 may be reduced after cross coupling, using standard methods like hydroboration or catalytic hydrogenation using catalysts such as palladium or platinum.
  • the coupling of P and Q may be effected using an appropriate organostannane (wherein Q may represent the stannate part) and ligand/catalyst such as 1,3-bis(diphenylphosphino)propane, palladium diacetate, lithium chloride and diphenylmethylphosphine and a leaving group such as aryl p-fluorobenzenesulfonate.
  • organostannane wherein Q may represent the stannate part
  • ligand/catalyst such as 1,3-bis(diphenylphosphino)propane, palladium diacetate, lithium chloride and diphenylmethylphosphine and a leaving group such as aryl p-fluorobenzenesulfonate.
  • A is a 5-membered ring having the general structure (ii) or (v), wherein X 1 is N
  • the 5-membered heterocycle may be coupled directly with the compound of formula (II) using a suitable catalyst such as Pd(OAc) 2 , PdCl 2 (PhCN) 2 , Pd(Ph 3 P) 4 and Cul. Coupling is carried out in presence of bases like sodium carbonate, potassium carbonate, piperidine and pyrrolidine using solvents such as OMF.
  • the hydroxyl function on the piperidine ring may be converted to a good leaving group such as tosyl, mesyl, triflate or halide by treatment with appropriate reagents like p-toluenesulfonylchloride, methanesulfonylchloride, triflic anhydride or PCI 5 in the presence of an appropriate organic or inorganic base like triethylamine, pyridine, K 2 CO 3 or Na 2 CO 3 , followed by ring contraction using a base such as sodium acetate in a solvent such as isopropanol.
  • a good leaving group such as tosyl, mesyl, triflate or halide
  • appropriate reagents like p-toluenesulfonylchloride, methanesulfonylchloride, triflic anhydride or PCI 5
  • an appropriate organic or inorganic base like triethylamine, pyridine, K 2 CO 3
  • the ring contraction involved in this step may be effected before flavone formation as depicted in Scheme 2 or it may be done after building the flavone with desired substitutions.
  • the compound of general formula (VIII) may be resolved by reacting it with a chiral auxiliary such as (+)-dibutyl tartaric acid, (+)-ketopinic acid, (+)-camphor-10-sulphonic acid or (+)-camphoric acid in the presence of a solvent such as methanol, isopropanol, diisopropyl ether, ethyl acetate or chloroform, crystallising out the required diastereomeric salt and subsequently treating with base such as NaHCO 3 .
  • a solvent such as methanol, isopropanol, diisopropyl ether, ethyl acetate or chloroform
  • the compound of formula (VIII) may then be treated with an acylating agent such as a carboxylic acid, an acid chloride, an acid anhydride or any activated form of an acid, in the presence of a Lewis acid catalyst such as BF 3 . Et 2 O, ZnCl 2 , AlCl 3 or TiCl 4 to obtain the corresponding acylated compound of formula (IX).
  • an acylating agent such as a carboxylic acid, an acid chloride, an acid anhydride or any activated form of an acid, in the presence of a Lewis acid catalyst such as BF 3 .
  • Et 2 O, ZnCl 2 , AlCl 3 or TiCl 4 to obtain the corresponding acylated compound of formula (IX).
  • the compound of formula (IX) can be converted to the compound of formula (X) by treating it with a reagent like an acid chloride of the type R 1 COCl, an anhydride of the type (R 1 CO) 2 O, an ester of the type R 1 COOCH 3 or any like reagent wherein R 1 is as defined hereinabove.
  • the said conversion can also be brought about by treating the compound of formula (IX) with an acid of the type R 1 COOH and phosphorus oxychloride in presence of an acid scavenger such as pyridine to obtain an acid chloride in situ under neutral conditions.
  • Conversion of the compound of formula (IX) to the compound of formula (X) can also be brought about by a combination of R 1 COOH and polyphosphoric acid.
  • the compound of the formula (IX) may be converted to that of the formula (XI) by standard ester hydrolysis using bases like KOH or NaOH in aqueous ethanol or methanol.
  • the resultant alcohol of formula (XI) may be converted to a ⁇ - diketone of formula (XII) by treatment with an appropriate carboxylic acid ester such as R 1 COOMe, R 1 COOEt etc.
  • X is a halogen or with an activated ester such as an anhydride in the presence of a base such as NaH in a solvent such as DMF, THF or 1,4-dioxane.
  • the ⁇ -diketone of formula (XII) may finally be converted into the required flavone of formula (XIII) by treatment with a strong acid such as concentrated HCl and subsequent treatment with a mild base such as Na 2 CO 3 , NaHCO 3 or K 2 CO 3 .
  • the intermediate of formula (X) may be converted into the flavone of formula (XIII) by treatment with a base such as NaH followed by cyclization using a strong acid like concentrated HCI followed by treatment with a mild base like Na 2 CO 3 , NaHCO 3 or K 2 CO 3 .
  • a base such as NaH
  • a strong acid like concentrated HCI
  • a mild base like Na 2 CO 3 , NaHCO 3 or K 2 CO 3 .
  • Scheme 3 outlines the preparation of the intermediate compound represented by formula (XVIII), which is subsequently converted to a compound of formula (XXII) by following similar process steps as described in Scheme 2 for the conversion of the compound of formula (VIII) to the compound of formula (XIII).
  • the compound of formula (XXII) as prepared herein is a compound of general formula (Ic) above wherein Z is O, A is a 5-membered ring corresponding to general structure (i), (iii) or (iv) wherein X 1 is C and X 2 is NR 13 , and the substitutions R 6 and R 7 on A are -CH 2 -OR 11 and H, respectively.
  • the compound of formula (XVIII) is prepared in three steps starting from an aldehyde of formula (XIV).
  • the compound of formula (XIV) is first converted into the compound of formula (XVII) in two steps involving condensation of the compound of formula (XIV) with an appropriate ketone using a Knoevenagel reaction, followed by a Michael reaction of the resulting intermediate of formula (XV) with nitromethane in the presence of base to obtain the compound of formula (XVII).
  • the Michael reaction in the presence of a chiral base such as proline leads to chiral compound of formula (XVII).
  • the compound of formula (XVII) can be obtained by first converting the aldehyde (XIV) into the corresponding nitrostyrene derivative of formula (XVI) which in turn is reacted with an appropriate ketone by a Michael reaction, using base as described above.
  • the resulting compound of formula (XVII) is then subjected to a sequence of reactions involving selective reduction of the nitro group by known methods such as treatment with Tin/HCl or Iron/HCl followed by cyclization and subsequent reduction to yield the compound of formula (XVIII).
  • a catalyst like Raney nickel directly gives the compound of formula (XVIII).
  • This pivotal intermediate is then converted to the compound of formula (XXII) as described in scheme 3.
  • Process steps from the compound of formula (XVIII) to the compound of formula (XXII) are as described for the conversion of the compound of formula (VIII) to the compound of formula (XIII) in scheme 2.
  • the compound of formula (XXXI) is prepared starting from the aldehyde of formula (XXIII).
  • the compound of formula (XXIII) is converted using a Wittig reaction to the corresponding styrene compound of formula (XXIV) which in turn is converted into the compound of formula (XXV) by a [3 + 2] cycloaddition with N-allyl N-chlorotosylamide in the presence of alkylboranes such as triethyl borane (Et 3 B) ( Oshima et. al. Org. Lett., 2001, 3, 2709-2711 ).
  • the compound of formula (XXV) is then converted into the compound of formula (XXXI) via the compounds of formulae (XXVI), (XXVII) and (XXVIII) as described in scheme 2.
  • the use of an alternative intermediate of formula (XXIX) also leads to the compound of formula (XXXI) by following the above cycloaddition route.
  • the compound of formula (XXXVI) is prepared starting from the compound of formula (XXXII).
  • the compound of formula (XXXII) on nitration provides the compound of formula (XXXIII) which on reduction gives the corresponding amino compound of formula (XXXIV) ( Larget et al, Bioorganic Med. Chem. Lett., 2000, 10, 835 ).
  • Conversion of amino flavone of formula (XXXIV) to the compound of formula (XXXV) may be effected by treatment with ethyl glyoxylate in methanol. Further conversion of the intermediate of formula (XXXV) to that of formula (XXXVI) may be brought about by employing the method described in the literature (Tet.
  • the key intermediate of formula (VIII), which corresponds to the compound of formula (XXXXIII) in Figure-6, may be prepared by the alternative process steps illustrated in scheme 6.
  • the compound of formula (XXXXIII) may be prepared starting from the chiral compound of formula (XXXVIII), which in turn is prepared in accordance with the procedure described in Syn. Commun., 1993, 23(20), 2839-2844 .
  • the compounds of the present invention are for use in regulating cell proliferation.
  • the compounds of the present invention are capable of inhibiting cell proliferation and are therefore useful in treating diseases which are due to an excessive or abnormal cell growth.
  • pathological conditions with excessive or abnormal cell proliferation against which the compounds of the invention can act to provide therapeutic benefits.
  • pathological conditions include:
  • the present compounds can be used in the treatment of differentiative disorders which result from, for example, de-differentiation of tissue, optionally accompanied by abortive reentry into mitosis.
  • Such degenerative disorders include chronic neurodegenerative diseases of the nervous system, including Alzheimers's disease as suggested by the finding that CDK5 is involved in the phosphorylation of tau protein ( J. BioChem. 1995, 117, 741-749 ), Parkinson's disease, Huntington's chorea, amylotrophic lateral sclerosis and the like, as well as spinocerebellar degenerations.
  • disorders associated with connective tissue such as those that may occur due to de-differentiation of chondrocytes or osteocytes, as well as vascular disorders which involve de-differentiation of endothelial tissue and smooth muscle cells, gastric ulcers characterized by degenerative changes in glandular cells, and renal conditions marked by failure to differentiate, e.g. Wilm's tumors.
  • the compounds of the present invention can be used as a cell culture additive for controlling proliferative and/or differentiation states of cells in vitro and can also be used for ex vivo tissue generation as for example, to enhance the generation of prosthetic tissue devices for implantation such as described in US-A-5 733 920 which is incorporated herein by reference.
  • Differential screening assays known in the art can be used to select for those compounds of the present invention with specificity for non-human CDK enzymes.
  • compounds which act specifically on eukaryotic pathogens e.g., anti-fungal or anti-parasitic agents, can be selected from the subject compounds of general formula (Ic).
  • Such inhibitors are useful in patients where fungal infections are a particular problem such as in patients with leukemias and lymphomas, diabetes mellitus, AIDS, or in people who are receiving immunosuppressive therapy.
  • the formulations of the inhibitors can be provided with those inhibitors which inhibit a cyclin-dependent kinase complex of the human pathogen with an IC 50 at least an order of magnitude less than an IC 50 for inhibition of a human cyclin-dependent kinase complex, though more preferably at least two or three orders of magnitude less.
  • certain of the present compounds can be selected on the basis of inhibitory specificity for insect or plant CDK's relative to the mammalian enzyme in a differential screen.
  • Such insect or plant CDK inhibitors of the present invention find use in insecticides and agricultural applications, respectively.
  • the present invention therefore also relates to the compounds of the formula (Ic) and/or their pharmaceutically acceptable salts for use as pharmaceuticals (or medicaments), to the use of the compounds of the formula (Ic) and/or their physiologically tolerable salts for the production of pharmaceuticals for the inhibition of cell proliferation or for the therapy or prophylaxis of the diseases mentioned above, for example for the production of pharmaceuticals for the therapy and prophylaxis of cancer, inflammation and arthritis, psoriasis, bone diseases, mycotic or viral infections, cardiovascular disorders, Alzheimers's disease, etc., and to methods of treatment aiming at such purposes including methods for said therapies and prophylaxes.
  • the present invention furthermore relates to pharmaceutical compositions that contain an effective amount of at least one compound of the formula (Ic) and/or its physiologically tolerable salts in addition to a customary pharmaceutically acceptable carrier, and to a process for the production of a pharmaceutical, which comprises bringing at least one compound of formula (Ic) into a suitable administration form using a pharmaceutically suitable and physiologically tolerable excipient and, if appropriate, further suitable active compounds, additives or auxiliaries.
  • the pharmaceutical preparation comprises the compound of formula (Ic) in an amount adequate to inhibit proliferation of a eukaryotic cell, which may be a mammalian cell, a human pathogen, such as Candida albicans, Aspergillus fumigatus, Rhizopus arrhizus, Mucor pusillus, an insect cell or a plant cell.
  • a eukaryotic cell which may be a mammalian cell, a human pathogen, such as Candida albicans, Aspergillus fumigatus, Rhizopus arrhizus, Mucor pusillus, an insect cell or a plant cell.
  • the present invention also relates to a method for the preparation of a medicament for the treatment or prevention of disorders associated with excessive cell proliferation, characterized in that at least one compound of the general formula (Ic) is used as the pharmaceutically active substance.
  • the pharmaceuticals can be administered orally, for example in the form of pills, tablets, coated tablets, capsules, granules or elixirs. Administration, however, can also be carried out rectally, for example in the form of suppositories, or parentally, for example intravenously, intramuscularly or subcutaneously, in the form of injectable sterile solutions or suspensions, or topically, for example in the form of solutions or transdermal patches, or in other ways, for example in the form of aerosols or nasal sprays.
  • compositions according to the invention are prepared in a manner known per se and familiar to one skilled in the art.
  • Pharmaceutically acceptable inert inorganic and/or organic carriers and/or additives can be used in addition to the compound(s) of the formula (Ic) and/or its physiologically tolerable salts.
  • Pharmaceutically acceptable inert inorganic and/or organic carriers and/or additives can be used in addition to the compound(s) of the formula (Ic) and/or its physiologically tolerable salts.
  • Carriers for soft gelatin capsules and suppositories are, for example, fats, wax, natural or hardened oils, etc.
  • Suitable carriers for the production of solutions for example injection solutions, or of emulsions or syrups are, for example, water, physiological sodium chloride solution or alcohols, for example, ethanol, propanol or glycerol, sugar solutions, such as glucose solutions or mannitol solutions, or a mixture of the various solvents which have been mentioned.
  • the pharmaceutical preparations normally contain about 1 to 99 %, preferably about 5 to 70%, most preferably from about 10 to about 30 % by weight of the compounds of the formula (Ic) and/or their physiologically tolerable salts.
  • the amount of the active ingredient of the formula (Ic) and/or its physiologically tolerable salts in the pharmaceutical preparations normally is from about 5 to 500 mg.
  • the dose of the compounds of this invention, which is to be administered can cover a wide range.
  • the dose to be administered daily is to be selected to suit the desired effect. About 20 to 1,000 mg are preferably administered daily per patient. If required, higher or lower daily doses can also be administered.
  • Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration without being toxic to the patient.
  • the selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and for materials used in combination with the particular compounds employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
  • the pharmaceutical preparations can contain additives such as, for example, fillers, antioxidants, dispersants, emulsifiers, defoamers, flavor corrigants, preservatives, solubilizers or colorants. They can also contain two or more compounds of the formula (Ic) and/or their physiologically tolerable salts. Furthermore, in addition to at least one compound of the formula (Ic) and/or its physiologically tolerable salts, the pharmaceutical preparations can also contain one or more other therapeutically or prophylactically active ingredients.
  • the compounds of the present invention may be used as drugs in the treatment of proliferative disorders either alone or as part of combined therapies.
  • the compounds of the present invention may be used in combination with known anti-cancer, cytostatic, and cytotoxic agents. If formulated as a fixed dose, such combination products employ the compounds of the present invention within the dosage range described above and the other pharmaceutically active agent within its approved dosage range.
  • the CDK inhibitor olomoucine has been found to act synergistically with known cytotoxic agents in inducing apoptosis ( J. Cell Sci., 1995, 108, 2897 ).
  • Compounds of general formula (Ic) may be used sequentially with known drugs such as anticancer or cytotoxic agents when a combination formulation is inappropriate.
  • (+/-)- trans -[1-Methyl-3-(2,4,6-trimethoxy-phenyl)-pyrrolidin-2-yl]-methanol (Compound No. 4) (27.3 g, 97.1 mmol), was dissolved in methanol (100 mL) and heated to 70°C. To this hot solution was added (+)DBTA (36.51 g, 101.9 mmol) and the heating was continued for 10 min. It was concentrated to get a solid (63.81 g), which was crystallized using methanol (45mL) and isopropanol (319mL).
  • (+/-)- trans -acetic acid 3-(3-acetyl-2-hydroxy-4,6-dimethoxy-pheny)-1-methyl-pyrrolidin-2-ylmethyl ester) (11 g, 31 mmol), obtained from compound (4) by the method described in example 6, in methanol (25 ml) was added with stirring, at room temperature, a 10% aqueous NaOH (25 mL, 62 mmol) solution. The temperature of the reaction mixture was raised to 50°C for 45 min. It was cooled to room temperature, acidified using concentrated HCI and concentrated to remove methanol. It was basified using a saturated aqueous. Na 2 CO 3 solution.
  • (+)- trans -1-[2-Hydroxy-3-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-4,6-dimethoxyphenyl]-1-ethanone was prepared from (+)- trans -[1-Methyl-3-(2,4,6-trimethoxy-phenyl)-pyrrolidin-2-yl]-methanol using the procedures described in examples 6 & 7.
  • (+)- trans -4-[5-Hydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-7-methoxy-4-oxo-4H-chromen-2-yl]-benzonitrile (Compound No. 36) and (+)- trans -4-[5,7-Dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-4-oxo-4H-chromen-2-yl]-benzonitrile. (Compound No. 37)
  • (+/-)- trans -2-(2-Bromo-5-methoxy-phenyl)-5,7-dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-chromen-4-one.
  • (+/-)- trans -2-(2-Bromo-5-hydroxy-phenyl)-5,7-dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-chromen-4-one
  • (+/-)- trans -Acetic acid 3-(3-acetyl-2-hydroxy-4,6-dimethoxy-phenyl)-1-methylpyrrolidin-2-ylmethyl ester (1.65 g, 4.7 mmol) was reacted with 2-chloro-3-pyridinecarboxylic acid (2.44 g, 15.49 mmol) in the presence of dry pyridine (25 mL) and POCl 3 (2.1 mL, 23.43 mmol) using the conditions described in example 52 to get trans -2-Chloro-nicotinic acid 2-(2-acetoxymethyl-1-methyl-pyrrolidin-3-yl)-6-acetyl-3,5-dimethoxy-phenyl ester.
  • Glacial acetic acid 75 mL was added dropwise with stirring, at 40-50°C to a mixture of compound(72) (15 g, 57.62 mmol) and iron dust (15 g, 0.267 mol) in water (120 mL).
  • the reaction mixture was stirred vigorously at room temperature for 1 h. It was poured into water (200 mL), basified using saturated aqueous Na 2 CO 3 solution and extracted with EtOAc (3x 250 mL). The organic extract was washed, dried (anhy. Na 2 SO 4 ) and concentrated to obtain the title compound (73). Yield: 12 g (90%).
  • Et 3 N (0.705 g, 7mmol) was added to a solution of compound(106) (1.5 g, 3.5 mmol) in dry CH 2 Cl 2 (25 mL) with stirring at (0-5°C), followed by a drop wise addition of methane sulfonyl chloride (0.479 g, 4.1 mmol).
  • the reaction mixture was, then stirred for 30 min. in an ice-bath, poured into ice water, extracted with EtOAc (2 X100 mL), washed with, brine, then a saturated aqueous NaHCO 3 solution, dried (anhy. Na 2 SO 4 ) and concentrated to obtain a syrup.
  • Et 3 N (0.352 g, 3.5 mmol) was added to a solution of compound(106) (1.0 g, 2.3 mmol) in dry CH 2 Cl 2 (20 mL) with stirring at (0-5°C), followed by a drop wise addition of methane sulfonyl chloride (0.319 g, 2.8 mmol).
  • the reaction mixture was then stirred for 30 min, at (0-5°C), diluted with CHCl 3 (100 mL), washed with, water, saturated aqueous NaHCO 3 solution, dried (anhy. Na 2 SO 4 ) and concentrated. The residue was dissolved in isopropanol (20 mL) and treated with KCN (0.925 g, 14.2 mmol).
  • reaction mixture was then stirred at 80°C for 1 h.
  • Aqueous FeCl 3 was added to destroy excess KCN. It was basified with aqueous Na 2 CO 3 , extracted with EtOAc (100mL x 3), washed with water, dried (anhy. Na 2 SO 4 ), and concentrated.
  • the crude obtained was purified using a silica gel column and 30% EtOAc +1 % liq. ammonia in CHC1 3 as an eluent to obtain the title compound(110).
  • (+/-)-trans-Acetic acid 4-[2-(2-chloro-phenyl)-5,7-dimethoxy-4-oxo-4H-chromen-8-yl]-1-cyano-piperidin-3-yl ester (Compound No. 127)
  • Methane sulfonyl chloride (0.178 g) was added to a mixture of compound(129) (0.55 g) and triethylamine (1 mL) in CHCl 3 (10 mL), with stirring, at 0°C. The reaction mixture was stirred for 1h. It was poured carefully into a cold saturated aqueous solution of Na 2 CO 3 . The organic layer was separated and the aqueous layer was extracted using CHCl 3 (2 x 50 mL). The combined organic extracts were washed with water, dried (anhy.
  • (+)-trans -Acetic acid 8-(2-acetoxymethyl-1-methyl-pyrrolidin-3-yl)-5-hydroxy-2-(4-nitro-phenyl)-4-oxo-4H-chromen-7-yl ester (Compound No. 162)
  • the efficacy of the present compounds in inhibiting the activity of cyclin-dependent kinases can be determined by a number of pharmacological assays well known in the art, such as described below or, for example, in Losiewics, M. D., et al. Biochem. Biophys. Res. Commun., 1994, 201, 589 .
  • the kinases, cyclins, and substrates used in the in vitro kinase assay can be proteins isolated from mammalian cells, or alternatively, they can be proteins produced recombinantly.
  • the exemplified pharmacological assays which follow hereinbelow have been carried out with the compounds of the present invention and their salts.
  • the assays measure phosphorylation of retinoblastoma protein (Rb) by CDK4 or CDK2 upon activation by cyclin D1 or cyclin E, respectively, through the transfer of ( ⁇ 32 P)- phosphate from ⁇ 32 P-ATP in a 96-well filter plate assay.
  • CDK4 or CDK2 was coexpressed with cyclin D1 or cyclin E, respectively, by a baculovirus expression system in insect cells.
  • 1 x 10 7 Sf9 cells were coinfected with baculoviruses containing human CDK-4 or 2 and cyclin D1 or E genes and after 72 hours cells were lysed in 500 ⁇ l of a lysis buffer (50 mM HEPES (pH 7.5), 10mM MgCl 2 , 1mM DTT, 5 ⁇ g/ml of aprotinin, 5 ⁇ g/ml of leupeptin, 0.1 mM NaF, 0.2 mM phenylmethylsulphonyl fluoride (PMSF), and sodium orthovanadate). Centrifuged lysate was purified on a GST- sepharose column. Purity of the proteins was checked by SDS-PAGE followed by western blots using specific antibodies (Santacruz Biotec, USA) to CDK4 or
  • GST-retinoblastoma (Rb) (aa 776-928) fusion protein is expressed in the bacteria E.coli and purified by GSH-Sepharose affinity chromatography. The GST-Rb bound to these beads served as the substrate in the assay.
  • Quantitation was by scintillation detection of ( 32 P)-GST-Rb in 96-well filter plates using Top Count scintillation 96-well counter (Packard; USA).
  • the CDK 4 or CDK 2 enzyme assay was run in 96-well format using Millipore Multiscreen filtration plates. All assay steps took place in a single filter plate (Unifilter plates, Packard, USA).
  • the filtration wells were pre-wet with kinase buffer (100 ⁇ l/well) and the solution was then removed by the application of vacuum, with the filter plate on a vacuum manifold and the vacuum on. 50 ⁇ l of GST-Rb bound to GSH-Sepharose beads in kinase buffer (0.5 ⁇ g GST-Rb/50 ⁇ l) was added to each well and vacuum was applied to removed the buffer.
  • a further 25 ⁇ l of a reaction mix containing ATP (cold + hot) and phosphatase inhibitors diluted in kinase buffer were added to each well, followed by the addition of test compound (4X final concentration in kinase buffer) or kinase buffer (control) in an additional 25 ⁇ l volume.
  • test compound 4X final concentration in kinase buffer
  • kinase buffer control
  • 50 ⁇ l (100 ng) of human CDK-4/D1 or CDK-2/E enzyme in kinase buffer was added to each well to initiate the reaction.
  • the reaction was incubated for 30 min at 30°C. After the reaction was complete, vacuum was applied and the plate was washed with the wash buffer (TNEN buffer) three times.
  • the filter plate was air-dried and placed in a Multiscreen adapter plate.
  • Table 2 NO COMPOUND NO IC 50 ( ⁇ M) HeLa Cervix MCF-7 Breast PC-3 Prostate MDAMB-231 Breast H460 Lung U-937 Histiocytic lymphoma (monocytes) 1 12 0.1-0.5 0.5-1 0.5-1 0.5-1 5.0-10 0.1-1 ++ NT ++ NT NT + 2 17 0.1-1 0.5-1 1.0-10 0.1 >10 0.1-1 + + NT NT NT + 3 Flavopiridol 0.1-0.5 0.5 0.05-0.1 0.1 0.05 0.1 +++ + ++ ++ + ++ NA: not active ⁇ 10 ⁇ M NT: not toxic ⁇ 30% + : 30-50% toxic ++ : 50-70% toxic +++: above 70% toxic.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Claims (25)

  1. Verbindung der allgemeinen Formel (Ic), Tautomer-Form, Stereoisomer, optisches Isomer, pharmazeutisch annehmbares Salz, pharmazeutisch annehmbares Solvat oder Polymorph davon,
    Figure imgb0047
     worin
    R1 steht für unsubstituiertes oder durch wenigstens einen Substituenten, gewählt aus Halogen, C1- bis C4-Alkyl, C1- bis C4-Alkoxy, C2- bis C6-Alkenyl, C3- bis C6-Alkinyl, C2- bis C4-Alkanoyl, Nitro, NR9R10, SR11, Trifluormethyl, Hydroxy, Cyano, Carboxy, C1- bis C4-Alkoxycarbonyl und -C1- bis C4-Alkylenhydroxy substituiertes Aryl, einen gesättigten, teilweise ungesättigten oder aromatischen Heterozyklus, der 1, 2, 3 oder 4 identische oder verschiedene Hetero-Atome aufweist, gewählt aus Stickstoff, Sauerstoff, Schwefel und Phosphor, worin der Heterozyklus unsubstituiert oder substituiert ist durch wenigstens einen Substituenten, der gewählt ist aus Halogen, C1- bis C4-Alkyl, C1- bis C4-Alkoxy, C2- bis C6-Alkenyl, C3- bis C6-Alkinyl, C2- bis C4-Alkanoyl, Nitro, NR9R10, SR11, Trifluormethyl, Hydroxy, Cyano, Carboxy, C1- bis C4-Alkoxycarbonyl und -C1- bis C4-Alkylenhydroxy; oder NR9R10;
    R2 steht für Wasserstoff, C1- bis C6-Alkyl, unsubstituiertes oder durch wenigstens einen Substituenten, gewählt aus Halogen, C1- bis C4-Alkyl, C1- bis C4-Alkoxy, C2- bis C6-Alkenyl, C3- bis C6-Alkinyl, C2- bis C4-Alkanoyl, Nitro, NR9R10, SR11, Trifluormethyl, Hydroxy, Cyano, Carboxy, C1- bis C4-Alkoxycarbonyl und -C1- bis C4-Alkylenhydroxy substituiertes Aryl, einen gesättigten, teilweise ungesättigten oder aromatischen Heterozyklus, der 1, 2, 3 oder 4 identische oder verschiedene Hetero-Atome aufweist, gewählt aus Stickstoff, Sauerstoff, Schwefel und Phosphor, und der unsubstituiert oder durch wenigstens einen Substituenten, gewählt aus Halogen, C1- bis C4-Alkyl, C1- bis C4-Alkoxy, C2- bis C6-Alkenyl, C3- bis C6-Alkinyl, C2- bis C4-Alkanoyl, Nitro, NR9R10, SR11, Trifluormethyl, Hydroxy, Cyano, Carboxy, C1- bis C4-Alkoxycarbonyl und -C1- bis C4-Alkylenhydroxy substituiert ist; OR11, Halogen, Cyano, Nitro, NR9R10 oder SR11; R3, R4 und R5 jeweils unabhängig voneinander gewählt sind aus Wasserstoff, C1- bis C6-Alkyl, Halogen, OR11, Aryl-C1- bis C4-Alkoxy, C1- bis C4-Alkylcarbonyloxy, C1- bis C4-Alkoxycarbonyloxy, Arylcarbonyloxy, Carboxy, Cyano, Nitro, NR9R10, SR11, Aryl-C1- bis C4-Alkylthio, SO2-C1- bis C4-Alkyl, SO2-Aryl, SO2NR9R10, Aryl und einen gesättigten, teilweise ungesättigten oder aromatischen Heterozyklus, der 1, 2, 3 oder 4 identische oder verschiedene Hetero-Atome aufweist, die gewählt sind aus Stickstoff, Sauerstoff, Schwefel und Phosphor;
    R6 für-C1- bis C4-AlkylenOR11 steht;
    R8 für Wasserstoff, C1- bis C4-Alkyl, Aryl, Carboxamid, Sulfonamid, NR9R10 oder OR11 steht;
    R9 und R10 jeweils unabhängig voneinander gewählt sind aus Wasserstoff, C1- bis C6-Alkyl, Aryl, C1- bis C4-Alkanoyl, einem Heterozyklus, der 1, 2, 3 oder 4 Hetero-Atome enthält, die gewählt sind aus Stickstoff, Sauerstoff, Schwefel und Phosphor, C1- bis C4-Alkoxycarbonyl, C1- bis C4-Alkylcarbonyl, Arylcarbonyl, Heterocyclocarbonyl, worin der Heterocyclo-Rest 1, 2, 3 oder 4 Hetero-Atome enthält, die gewählt sind aus Stickstoff, Sauerstoff, Schwefel und Phosphor, Carboxamid und Sulfonamid, worin der Aryl-Rest und der Heterozyklus oder der Heterocyclo-Rest entweder unsubstituiert oder durch wenigstens einen Substituenten substituiert sind, der gewählt ist aus Halogen, C1-bis C4-Alkyl, C1- bis C4-Alkoxy, C2- bis C6-Alkenyl, C3- bis C6-Alkinyl, C2- bis C4-Alkanoyl, Nitro, NR9R10, SR11, Trifluormethyl, Hydroxy, Cyano, Carboxy, C1- bis C4-Alkoxycarbonyl und -C1- bis C4-Alkylenhydroxy; oder
    R9 und R10, zusammen mit dem Stickstoff-Atom, an das sie gebunden sind, einen heterozyklischen Ring bilden, der wenigstens ein weiteres Hetero-Atom aufweisen kann, das gewählt ist aus Stickstoff, Sauerstoff und Schwefel, und der gesättigt, teilweise ungesättigt oder aromatisch ist, wobei der heterozyklische Ring entweder unsubstituiert ist oder substituiert ist durch wenigstens einen Substituenten, der gewählt ist aus Halogen, C1- bis C4-Alkyl, C1- bis C4-Alkoxy, C2- bis C6-Alkenyl, C3- bis C6-Alkinyl, C2- bis C4-Alkanoyl, Nitro, NR9R10, SR11, Trifluormethyl, Hydroxy, Cyano, Carboxy, -C1- bis C4-Alkoxycarbonyl und -C1- bis C4-Alkylenhydroxy;
    R11 steht für Wasserstoff, C1- bis C6-Alkyl, C1- bis C4-Alkanoyl, unsubstituiertes oder durch wenigstens einen Substituenten, gewählt aus Halogen, C1- bis C4-Alkyl, C1- bis C4-Alkoxy, C2- bis C6-Alkenyl, C3- bis C6-Alkinyl, C2- bis C4-Alkanoyl, Nitro, NR9R10, SR11, Trifluormethyl, Hydroxy, Cyano, Carboxy, C1- bis C4-Alkoxycarbonyl und -C1-bis C4-Alkylenhydroxy substituiertes Aryl oder C1- bis C4-Alkoxycarbonyl;
    Z für ein Wasserstoff-Atom, ein Schwefel-Atom oder NR8 steht;
    A für einen 5-gliedrigen Ring steht, worin
    der 5-gliedrige Ring gesättigt oder ungesättigt ist und wiedergegeben wird durch irgendeine der allgemeinen Strukturen (i) bis (v);
    Figure imgb0048
     worin X1 und X2 jeweils unabhängig voneinander gewählt sind aus einem Kohlenstoff-Atom und einem Hetero-Atom, das gewählt ist aus einem Sauerstoff-Atom, einem Schwefel-Atom, S(O)p und einem Stickstoff-Atom, mit der Maßgabe, dass in den Strukturen (i), (iii) und (iv) wenigstens einer der Reste X1 und X2 für ein Hetero-Atom steht, und dann, wenn das Hetero-Atom ein Stickstoff-Atom ist, dieses wenigstens monosubstituiert ist durch R13, worin R13 gewählt ist aus Wasserstoff, unsubstituiertes oder durch wenigstens einen Substituenten, gewählt aus Halogen, Hydroxy, Carboxy, C1- bis C4-Alkoxy, Amino, Nitro, C1- bis C4-Alkylthio, Sulfhydryl und Sulfonyl substituiertes C1- bis C6-Alkyl, unsubstituiertes oder durch wenigstens einen Substituenten, gewählt aus Halogen, Hydroxy, Carboxy, C1- bis C4-Alkoxy, Amino, Nitro, C1- bis gewählt aus Halogen, Hydroxy, Carboxy, C1- bis C4-Alkoxy, Amino, Nitro, C1- bis C4-Alkylthio, Sulfhydryl und Sulfonyl, substituiertes C2- bis C6-Alkenyl, unsubstituiertes oder durch wenigstens einen Substituenten, gewählt aus Halogen, C1- bis C4-Alkyl, C1-bis C4-Alkoxy, C2- bis C6-Alkenyl, C3- bis C6-Alkinyl, C2- bis C4-Alkanoyl, Nitro, NR9R10, SR11, Trifluormethyl, Hydroxy, Cyano, Carboxy, C1- bis C4-Alkoxycarbonyl und -C1- bis C4-Alkylenhydroxy, substituiertes Aryl, Hydroxy, C1- bis C4-Alkoxy, C1-bis C4-Alkylcarbonyl, Cyano, -SO2R10 und -CO-(CH2)m-R14;
    R6 für einen Substituenten steht, wie er oben definiert wurde, an wenigstens einem Kohlenstoff-Atom-Ring-Glied;
    R7 steht für Wasserstoff, C1- bis C4-Alkyl, C1- bis C4-Alkylcarbonyl oder Arylcarbonyl;
    R14 steht für Wasserstoff, C1- bis C4-Alkyl, Hydroxy, NR9R10, Halogen, -SH, -S-C1- bis C4-Alkyl, -S-Aryl, Aryl, worin der Aryl-Rest unsubstituiert ist oder substituiert ist durch wenigstens einen Substituenten, der gewählt ist aus Halogen, C1- bis C4-Alkyl, C1- bis C4-Alkoxy, C2- bis C6-Alkenyl, C3- bis C6-Alkinyl, C2- bis C4-Alkanoyl, Nitro, NR9R10, SR11, Trifluormethyl, Hydroxy, Cyano, Carboxy, C1- bis C4-Alkoxycarbonyl und -C1-bis C4-Alkylenhydroxy, einen Heterozyklus, der 1, 2, 3 oder 4 Hetero-Atome enthält, die gewählt sind aus Stickstoff, Sauerstoff, Schwefel und Phosphor, wobei der Heterozyklus unsubstituiert ist oder substituiert ist durch wenigstens einen Substituenten, der gewählt ist aus Halogen, C1- bis C4-Alkyl, C1- bis C4-Alkoxy, C2- bis C6-Alkenyl, C3- bis C6-Alkinyl, C2- bis C4-Alkanoyl, Nitro, NR9R10, SR11, Trifluormethyl, Hydroxy, Cyano, Carboxy, C1- bis C4- Alkoxycarbonyl und -C1- bis C4-Alkylenhydroxy;
    p eine ganze Zahl im Bereich von 1 oder 2 ist; und
    m eine ganze Zahl von 0 bis 6 ist.
  2. Verbindung der Formel (Ic) wie in Anspruch 1 beansprucht, worin
    R1 steht für Phenyl, das unsubstituiert ist oder substituiert ist durch 1, 2, oder 3 identische(n) oder verschiedene(n) Substituent(en), gewählt aus Halogen, C1- bis C4-Alkyl, C1- bis C4-Alkoxy, Nitro, NR9R10, SR11, Trifluormethyl, Hydroxy, Cyano, Carboxy, C1- bis C4-Alkoxycarbonyl und -C1- bis C4-Alkylenhydroxy, oder für einen Heterozyklus steht, der ein gesättigter, teilweise ungesättigter oder aromatischer Ring ist, der 5 oder 6 Ring-Atome enthält, von denen 1, 2 oder 3 identische oder verschiedene Hetero-Atome sind, die gewählt sind aus Stickstoff, Sauerstoff, Schwefel und Phosphor, und worin der Heterozyklus unsubstituiert ist oder substituiert ist durch 1, 2 oder 3 identische oder verschiedene Substituenten, die gewählt sind aus Halogen, C1- bis C4-Alkyl, C1- bis C4-Alkoxy, Nitro, NR9R10, SR11, Trifluormethyl, Hydroxy, Cyano, Carboxy, C1- bis C4- Alkoxycarbonyl und -C1- bis C4-Alkylenhydroxy;
    R2 steht für Wasserstoff, C1- bis C6-Alkyl, Phenyl, das unsubstituiert ist oder substituiert ist durch 1, 2 oder 3 identische oder verschiedene Substituenten, die gewählt sind aus Halogen, C1- bis C4-Alkyl, C1- bis C4-Alkoxy, Nitro, NR9R10, SR11, Trifluormethyl, Hydroxy, Cyano, Carboxy, C1- bis C4- Alkoxycarbonyl und -C1- bis C4-Alkylenhydroxy, OR11, Halogen, Cyano, Nitro, NR9R10 oder SR11;
    R3, R4 und R5 jeweils unabhängig voneinander gewählt sind aus Wasserstoff, C1- bis C4-Alkyl, Halogen, OR11, C1- bis C4-Alkylcarbonyloxy, NR9R10, SO2NR9R10, Carboxy, Cyano und Nitro;
    Z für ein Sauerstoff-Atom oder ein Schwefel-Atom steht;
    A für einen 5-gliedrigen Ring steht, worin
    in dem 5-gliedrigen gesättigten oder ungesättigten Ring, der wiedergegeben wird durch eine der allgemeinen Strukturen (i) bis (v), wie sie in Anspruch 1 beansprucht wurden, X1 und X2 jeweils unabhängig voneinander gewählt sind aus einem Kohlenstoff-Atom und einem Hetero-Atom, das gewählt ist aus Sauerstoff, Schwefel und Stickstoff, mit der Maßgabe, dass in den Strukturen (i), (iii) und (iv) wenigstens einer der Reste X1 und X2 ein Hetero-Atom ist, und dass dann, wenn das Hetero-Atom ein Stickstoff-Atom ist, dieses wenigstens monosubstituiert ist durch R13, worin R13 steht für Wasserstoff unsubstituiertes C1- bis C6-Alkyl oder C1- bis C6-Alkyl, das substituiert ist durch Halogen, Hydroxy oder Carboxy, C2- bis C6-Alkenyl, Hydroxy, C1- bis C6-Alkoxy, C1-bis C4-Alkylcarbonyl, Toluolsulfonyl, Cyano, SO2R10, -CO(CH2)mR14 und Phenyl, das unsubstituiert ist oder substituiert ist durch wenigstens einen Substituenten, der gewählt ist aus Halogen, C1- bis C4-Alkyl, C1- bis C4-Alkoxy, Nitro, NR9R10, SR11, Trifluormethyl, Hydroxy, Cyano, Carboxy, C1- bis C4- Alkoxycarbonyl und -C1- bis C4-Alkylenhydroxy, und R7 für Wasserstoff steht;
    R9 und R10 jeweils unabhängig voneinander gewählt sind aus C1- bis C4-Alkyl, C1- bis C4-Alkanoyl, C1- bis C4-Alkoxycarbonyl, C1- bis C4-Alkylcarbonyl, Carboxamid und Sulfonamid oder
    R9 und R10 zusammen mit dem Stickstoff-Atom, an das sie gebunden sind, einen 3-, 4-, 5- oder 6-gliedrigen heterozyklischen Ring bilden, der wenigstens ein weiteres Hetero-Atom aufweisen kann, das gewählt ist aus Stickstoff, Sauerstoff und Schwefel, wobei der Ring gesättigt ist, teilweise ungesättigt ist oder aromatisch ist und entweder unsubstituiert ist oder substituiert ist durch wenigstens einen Substituenten, der gewählt ist aus Halogen, C1- bis C4-Alkyl, C1- bis C4-Alkoxy, C2- bis C6-Alkenyl, C3- bis C6-Alkinyl, C2- bis C4-Alkanoyl, Nitro, NR9R10, SR11, Trifluormethyl, Hydroxy, Cyano, Carboxy, C1- bis C4- Alkoxycarbonyl und -C1- bis C4-Alkylenhydroxy;
    R11 steht für Wasserstoff, C1- bis C4-Alkyl, C1- bis C4-Alkanoyl oder C1- bis C4-Alkoxycarbonyl; und
    R14 steht für Wasserstoff, C1- bis C4-Alkyl, Hydroxy, -NR9R10, Halogen, -SH oder -S-C1- bis C4-Alkyl.
  3. Verbindung der Formel (Ic), wie in Anspruch 1 oder Anspruch 2 beansprucht ist, worin A für einen 5-gliedrigen gesättigten oder ungesättigten Ring steht, der durch irgendeine der allgemeinen Strukturen (i) bis (iv) wiedergegeben wird:
    Figure imgb0049
     worin
    X1 entweder ein Kohlenstoff-Atom oder ein Hetero-Atom ist, das gewählt ist aus Sauerstoff, Schwefel und Stickstoff, mit der Ausnahme, dass in Struktur (iv) X1 entweder ein Kohlenstoff-Atom oder ein Stickstoff-Atom ist und R6 und R13 wie definiert sind.
  4. Verbindung der Formel (Ic), wie in irgendeinem der vorangehenden Ansprüche beansprucht, worin R1 Phenyl ist, das unsubstituiert ist oder substituiert ist durch 1, 2, oder 3 identische(n) oder verschiedene(n) Substituent(en), gewählt aus Halogen, C1- bis C4-Alkyl, C1- bis C4-Alkoxy, Nitro, NR9R10, SR11, Trifluormethyl, Hydroxy, Cyano, Carboxy, C1- bis C4- Alkoxycarbonyl und -C1- bis C4-Alkylenhydroxy, oder ein Heterozyklus ist, der ein gesättigter, teilweise ungesättigter oder aromatischer Ring ist, der 6-Ring-Atome enthält, von denen 1, 2 oder 3 identische oder verschiedene Hetero-Atome sind, die gewählt sind aus Stickstoff, Sauerstoff und Schwefel, und worin der Heterozyklus unsubstituiert ist oder substituiert ist durch 1, 2 oder 3 identische(n) oder verschiedene(n) Substituent(en), gewählt aus Halogen, C1- bis C4-Alkyl, C1- bis C4-Alkoxy, Nitro, NR9R10, SR11, Trifluormethyl, Hydroxy, Cyano, Carboxy, C1- bis C4-Alkoxycarbonyl und -C1- bis C4-Alkylenhydroxy;
    R2 und R4 Wasserstoff sind; und
    R3 und R5 jeweils unabhängig voneinander gewählt sind aus Hydroxy, C1- bis C4-Alkoxy und C1- bis C4-Alkylcarbonyloxy.
  5. Verbindung der Formel (Ic), wie in irgendeinem der vorangehenden Ansprüche beansprucht, worin R1 Phenyl oder Pyridinyl ist, substituiert durch 1, 2 oder 3 identische(n) oder verschiedene(n) Substituent(en), gewählt aus Halogen und Nitro, R2 und R4 Wasserstoff sind, R3 und R5 Hydroxy sind, A ein gesättigter 5-gliedriger Ring ist, der wiedergegeben wird durch irgendeine der allgemeinen Strukturen (i) bis (v), worin X1, X2, R6 und R13 wie definiert sind.
  6. Verbindung nach Anspruch 5, worin X1 Kohlenstoff ist, X2 Stickstoff ist, R6 -C1- bis C4-Alkylenhydroxy ist, R13 C1- bis C4-Alkyl ist und Z ein Sauerstoff-Atom ist.
  7. Verbindung der allgemeinen Formel (Ic) gemäß irgendeinem der vorangehenden Ansprüche, welche ist:
    (+/-)-trans-2-(2-Chlorphenyl-)8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)5,7-dimethoxy-chromen-4-on;
    (+)-trans-2-(2-Chlorphenyl-)8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)5,7-dimethoxy-chromen-4-on;
    (+)-trans-2-(2-Chlorphenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methylpyrrolidin-3-yl-)chromen-4-on;
    (-)-trans-2-(2-Chlorphenyl-)8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)5,7-dimethoxy-chromen-4-on;
    (-)-trans-2-(2-Chlorphenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)chromen-4-on;
    (+)-trans-2-(2-Bromphenyl-)8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)5,7-dimethoxy-chromen-4-on ;
    (+)-trans-2-(2-Bromphenyl-)5,7-dihydroxy-8- (2-hydroxymethyl-1-methyl- pyrrolidin-3-yl-)chromen-4-on;
    (+)-trans-2-(4-Brornphenyl-)8-(2-hydroxymethyl-l-methyl-pyrrolidin-3-yl-)5,7-dimethoxy-chromen-4-on;
    (+)-trans-2-(4-Bromphenyl-)5-hydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-) 7-methoxy-chromen-4-on;
    (+)-trans-2-(4-Bramphenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methyl- pyrrolidin-3-yl-)chromen-4-on ;
    (+)-trans-2-(3-Chlorphenyl-)8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)5,7-dimethoxy-chromen-4-on;
    (+)-trans-2-(3-Chlorphenyl-)5-hydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-) 7-methoxy-chromen-4-on;
    (+)-trans-2-(3-Chlorphenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methyl- pyrrolidin-3-yl-)chromen-4-on ;
    (+)-trans-8-(2-Hydroxymethyl-1-methyl-pyrrolidin-3-yl-)2-(2-iodo-phenyl-)5,7-dimethoxy-chromen-4-on;
    (+)-trans-5,7-Dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)2-(2-iod-phenyl-)-chromen-4-on;
    (+)-trans-2-(2-Fluorphenyl-)8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)5,7-dimethoxy-chromen-4-on;
    (+)-trans-2-(2-Fluorphenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)ehromen-4-on;
    (+)-trans-2-(3-Fluorphenyl-)5,7-dimethoxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)chromen-4-on;
    (+)-trans-2-(3-Fluorphenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)chromen-4-on;
    (+)-trans-2-(2,6-Difluorphenyl-)8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)5,7-dimethoxy-chromen-4-on;
    (+)-trans-2-(2,6-Difluorphenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)chromen-4-on;
    (+/-)-trans-4-[8-(2-Hydroxymethyl-1-methyl-pyrrolidin-3-yl-)5,7-dimethoxy-4-oxo-4H-chromen-2-yl-]benzonitril;
    (+/-)-trans-4-[5,7-Dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)4-oxo-4H-chromen-2-yl-]benzonitril;
    (+)-trans-4-[8-(2-Hydroxymethyl-1-methyl-pyrrolidin-3-yl-)5,7-dimethoxy-4-oxo-4H-chromen-2-yl-]benzonitril;
    (+)-trans-4-[5,7-Dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)-4-oxo-4H-chromen-2-yl-]benzonitril;
    (+/-)-trans-8-(2-Hydroxymethyl-1-methyl-pyrrolidin-3-yl-)5,7-dimethoxy-2-(4-trifluormethyl-phenyl-chromen-4-on;
    (+/-)-trans-5,7-Dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)2-(4-trifluormethyl-phenyl-)chromen-4-on;
    (+)-trans-8-(2-Hydroxymethyl-1-methylpyrrolidin-3-yl-)5,7-dimethoxy-2-(4-trifluormethyl-phenyl-)chromen-4-on;
    (+)-trans-5,7-Dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)2-(4-trifluormethyl-phenyl-)chromen-4-on;
    (-)-trans-8-(2-Hydroxymethyl-1-methylpyrrolidin-3-yl-)5, 7-dimethoxy-2-(4-trifluormethyl-phenyl-)chromen-4-on;
    (-)-trans-5,7-Dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)2-(4-trifluormethyl-phenyl-)chromen-4-on;
    (+)-trans-8-(2-Hydroxymethyl-1-methylpyrrolidin-3-yl-)5,7-dimethoxy-2-phenyl-chromen-4-on;
    (+)-trans-5,7-Dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)2-phenyl-chromen-4-on;
    (+)-trans-8-(2-Hydroxymothyl-1-methylpyrrolidin-3-yl-)5,7-dimethoxy-2-thiophen-2-yl-chromen-4-on ;
    (+)-trans-5,7-Dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)2-thiophen-2-yl-chromen-4-on;
    (+)-trans-4-[5,7-Dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)4-oxo-4H-chromen-2-yl-]3-methyl-benzonitril;
    (+)-trans-4-[8-(2-Hydroxymethyl-1-methyl-pyrrolidin-3-yl-)5,7-dimethoxy-4-oxo-4H-chromen-2-yl-]3-methyl-benzonitril;
    (+/-)-trans-2-(2-Brom-5-methoxyphenyl-)8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)5,7-dimethoxy-chromen-4-on;
    (+/-)-trans-2-(2-Brom-5-methoxyphenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methylpyrrolidin-3-yl-)chromen-4-on;
    (+)-trans-2-(2-Brom-5-methoxyphenyl-)8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-) 5,7-dimethoxy-chromen-4-on;
    (+)-trans-2-(2-Brom-5-methoxyphenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methylpyrrolidin-3-yl-)chromen-4-on;
    (+/-)-trans-2-(2-Brom-5-hydroxyphenyl-)-5,7-dihydroxy-8-(2-hydroxymethyl-1-methylpyrrolidin-3-yl-)chromen-4-on;
    (+)-trans-2-(2-Brom-5-hydroxyphenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methylpyrrolidin-3-yl-)chromen-4-on;
    (+/-)-trans-2-[(3,5-Bis-trifluormethyl-)phenyl-]8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)5,7-dimethoxy-chromen-4-on;
    (+/-)-trans-2-[(3,5-Bis-trifluormethyl-)phenyl-]5,7-dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)chromen-4-on;
    (+)-trans-2-(2-Chlor-5-methylphenyl-)8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-) 5,7-dimethoxy-chromen-4-on;
    (+)-trans-2-(2-Chlor-5-methylphenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methylpyrrolidin-3-yl)chromen-4-on;
    (+)-trans-2-(2-Brom-5-nitrophenyl-)8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)5,7-dimethoxy-chromen-4-on;
    (+)-trans-2-(2-Brom-5-nitrophenyl-)8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)5,7-dihydroxy-chromen-4-on;
    (+/-)-trans-2-(2-Chlorpyridin-3-yl-)8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)5,7-dimethoxy-chromen-4-on;
    (+/-)-trans-2-(2-Chlorpyridin-3-yl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)chromen-4-on;
    (+/-)-trans-2-(2-Brom-5-nitrophenyl-)8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-) 5,7-dihydroxy-chromen-4-on;
    (+)-trans-2-(2-Chlorpyridin-3-yl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)chromen-4-on;
    (+/-)-trans-8- (2-Hydroxymethyl-1-methyl-pyrrolidin-3-yl-)5,7-dimethoxy-2-(4-nitrophenyl-)4H-chromen-4-on;
    (+/-)-trans-5,7-Dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)2-(4-nitrophenyl-)chromen-4-on;
    (+/-)-trans-2-(4-Aminophenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)chromen-4-on;
    (+/-)-trans-8-(2-Hydroxymethyl-1-methyl-pyrrolidin-3-yl-)5,7-dimethoxy-2-(2-methoxy-phenyl-)chromen-4-on;
    (+/-)-trans-5,7-Dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)2-(2-hydroxyphenyl-)chromen-4-on;
    (+)-trans-3-Chlor-4-[8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)5,7-dimethoxy-4-oxo-4H-chromen-2-yl-]benzonitril;
    (+)-trans-3-Chlor-4-[5,7-dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)4-oxo-4H-chromen-2-yl-]benzonitril;
    (+)-trans-2-(4-Brom-2-chlorphenyl-)8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)5,7-dimethoxy-chromen-4-on;
    (+)-trans-2-(4-Brom-2-chlorphenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methylpyrrolidin-3-yl-)ehromen-4-on;
    (+/-)-trans-2-(2-Chlor-5-dimethylaminophenyl-)8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)5,7-dimethoxy-chromen-4-on;
    (+/-)-trans-2-(2-Chlor-5-methylaminphenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)chromen-4-on;
    (+/-)-trans-2-(2-Chlor-4-methoxyphenyl-)8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)5, 7-dimethoxy-chromen-4-on;
    (+/-)-trans-2-(2-Chlor-4-hydroxyphenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methylpyrrolidin-3-yl-)chromen-4-on;
    (+/-)-trans-2-(2-Chlor-5-fluorphenyl-)8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-) 5,7-dimethoxy-chromen-4-on;
    (+/-)-trans-2-(2-Chlor-5-fluorphenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methylpyrrolidin-3-yl-)chromen-4-on;
    (+/-)-trans-2-(2-Chlor-5-methoxy-phenyl-)8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)5,7-dxmethoxy-chromen-4-on;
    (+/-)-trans-2-(2-Chlor-5-hydroxy-phenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methylpyrrolidin-3-yl-)chromen-4-on;
    (+/-)-trans-2-(2-Chlor-5-methoxy-phenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-ethyl-pyrrolidin-3-yl-)chromen-4-on;
    (+/-)-trans-8-(2-Azidomethyl-1-methyl-pyrrolidin-3-yl-)2-(2-Chlorphenyl-)5,7-dimethoxy-chromen-4-on;
    (+/-)-trans-8-(2-Aminomethyl-1-methyl-pyrrolidin-3-yl-)2-(2-Chlorphenyl-)5,7-dimethoxy-chromen-4-on;
    (+/-)-trans-8- (2-Aminomethyl-1-methyl-pyrrolidin-3-yl-)2- (2-Chlorphenyl-)5, 7- dihydroxy-chromen-4-on;
    (+/-)-trans-3-{2-(2-Chlorphenyl-)5,7-dimethoxy-4-oxo-4H-chromen-8-yl-]1-methylpyrrolidin-2-yl-}acetonitril;
    (+/-)-trans-{3-[2-(2-Chlorphenyl-)5,7-dihydroxy-4-oxo-4H-chromen-8-yl-]1-methylpyrrolidin-2-yl-}acetonitril;
    (+/-)-trans-2-(2-Chlorphenyl-)8-(2-imidazol-1-ylmethyl-1-methyl-pyrrolidin-3-yl-)5,7-dimethoxy-chromen-4-on;
    (+/-)-trans-2-(2-Chlorphenyl-)5,7-dihydroxy-8-(2-imidazol-1-ylmethyl-1-methyl-pyrrolidin-3-yl-)chromen-4-on;
    (+/-)-trans-2-[2-Chlorphenyl-8-(2-mercaptomethyl-1-methyl-pyrrolidin-3-yl-)]5,7-dimethoxy-chromen-4-on;
    (+/-)-trans-2-(2-Chlorphenyl-)5,7-dihydroxy-8-(2-mercaptomethyl-1-methyl-pyrrolidin-3-yl-)chromen-4-on;
    (+/-)-trans-Essigsäure3-[2-(2-Chlorphenyl-)5,7-dimethoxy-4-oxo-4H-chromen-8-yl-]1-(4-methoxy-phenyl-)pyrrolidin-2-ylmethylester;
    (+/-)-trans-2-(2-Chlorphenyl-)8-[2-hydroxymethyl-1-(4-methoxy-phenyl-)pyrrolidin-3-yl-]5,7-dimethoxy-chromen-4-on;
    (+/-)-trans-2-(2-Chlorphenyl-)5,7-dihydroxy-8-[2-hydroxymethyl-1-(4-methoxyphenyl-)pyrrolidin-3-yl-]chromen-4-on;
    (+/-)-trans-Essigsäure-3-[2-(2-Chlorphenyl-)5,7-dimethoxy-4-oxo-4H-chromen-8-yl-]1-propyl-pyrrolidin-2-ylmethylester;
    (+/-)-trans-2-(2-Chlorphenyl-)8-(2-hydroxymethyl-1-propyl-pyrrolidin-3-yl-)5,7-dimethoxy-chromen-4-on;
    (+/-)-trans-2-(2-Chlorphenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-propyl-pyrrolidin-3-yl-)ehromen-4-on;
    (+/-)-trans-2-(2-Chlor-4-nitrophenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methylpyrrolidin-3-yl-)chromen-4-on;
    (+/-)-trans-2-(2-Brom-4-nitrophenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methy)-pyrrolidin-3-yl-)chromen-4-on;
    (+/-)-trans-3-Chlor-4-[5,7-dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)4-oxo-4H-chromen-2-yl-]-benzoesäure;
    (+/-)-trans-3-Brom-4-[5,7-dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)4-oxo-4H-chromen-2-yl-]benzoesäure;
    (+/-)-trans-2-(2-Chlor-4-fluorphenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methylpyrrolidin-3-yl-)chromen-4-on;
    (+/-)-trans-2-(4-Amino-2-chlorphenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methylpyrrolidin-3-yl-)chromen-4-on;
    (+/-)-trans-2-(2-Brom-4-fluorphenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methylpyrrolidin-3-yl-)chromen-4-on;
    (+/-)-trans-2-(4-Amino-2-bromphenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methylpyrrolidin-3-yl-)chromen-4-on;
    (+/-)-trans-4-Chlor-3-[5,7-dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)4-oxo-4H-chromen-2-yl-]benzoesäure;
    (+/-)-trans-4-Brom-3- [5,7-dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)4-oxo-4H-chromen-2-yl-]benzoesäure;
    (+/-)-trans-4-Brom-3-[5,7-dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)4-oxo-4H-chromen-2-yl-]N-hydroxy-benzamid;
    (+/-)-trans-4-Chlor-3-[5,7-dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)4-oxo-4H-chromen-2-yl-]N-hydroxy-benzamid;
    (+/-)-trans-3-Chlor-4-[5,7-dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)4-oxo-4H-chromen-2-yl-]N-hydroxy-benzamid;
    (+/-)-trans-3-Brom-4-[5,7-dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)4-oxo-4H-chromen-2-yl-]N-hydroxy-benzamid;
    (+1-)-trans-2-(2,4-Difluorphenyl)-5,7-dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)chromen-4-on;
    (+)-trans-2-(2-Chlor-3-fluorphenyl-)8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)5,7-dimethoxy-chromen-4-on;
    (+)-trans-2-(2-Chlor-3-fluorphenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrro-lidin-3-yl-)chromen-4-on;
    (+)-trans-2-(2-Brom-3-fluorphenyl-)8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)5,7-dimethoxy-chromen-4-on;
    (+)-trans-2-(2-Brom-3-fluorphenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methylpyrrolidin-3-yl-)chromen-4-on;
    (+)-trans-2-(2-Brom-5-fluorphenyl-)8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)5,7-dimethoxy-chromen-4-on;
    (+)-trans-2-(2-Brom-5-fluorphenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methylpyrrolidin-3-yl-)ehromen-4-on;
    (+)-trans-2-(2-Chlor-5-iodphenyl-)8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)5,7-dimethoxy-chrornen-4-on;
    (+)-trans-2-(2-Chlor-5-iodphenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-)chromen-4-on;
    (+)-trans-2-(2-Brom-5-Chlorphenyl-)8-(2-hydroxymethyl-1-methyl-pyrrolidin-2-yl-) 5,7-dimethoxy-chromen-4-on;
    (+)-trans-2-(2-Brom-5-Chlorphenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methylpyrrolidin-3-yl-)chromen-4-on;
    (+/-)-trans-2-(2-Chlorphenyl-)5,7-dihydroxy-8-(2-hydraxymethyl-1-methyl-1-oxy-pyrrolidin-3-yl-)chromen-4-on;
    (+)-trans-2-(2-Brom-4-nitrophenyl-)8-(2-hydroxymethyl-1-methylpyrrolidin-3-yl-)5,7-dimethoxy-chromen-4-on;
    (+)-trans-2-(2-Brom-4-nitrophenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methylpyrrolidin-3-yl-)chromen-4-on;
    (+)-trans-2-(4-Amino-2-Bromphenyl-)8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-) 5,7-dimethoxy-chromen-4-on;
    (+)-trans-2-(4-Amino-2-Bromphenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methylpyrrolidin-3-yl-)chromen-4-on;
    (+)-trans-2-(2-Brom-4-methoxyphenyl-)8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl-) 5,7-dimethoxy-chromen-4-on;
    (+)-trans-2-(2-Brom-4-methoxyphenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methylpyrrolidin-3-yl-)chromen-4-on;
    (+)-trans-2-(2-Brom-4-hydroxyphenyl-)5,7-dihydroxy-8-(2-hydroxymethyl-1-methylpyrrolidin-3-yl-)chromen-4-on;
    (+)-trans-Essigsäure-8-(2-acetoxymethyl-1-methylpyrrolidin-3-yl-)5-hydroxy-2-(4-nitro-phenyl-)4-oxo-4H-chromen-7-ylester;
    (+)-trans-2-(2,4-Dichlor-5-fluorphenyl-)-8-(2-hydroxymenyl-1-methyl-pyrrolidin-3-yl-) 5,7-dimethoxy-chromen-4-on; oder
    (+)-trans-2-(2,4-Dichlor-5-fluorphenyl-5,7-dihydroxy-8-(2-hydroxymethyl-1-methylpyrrolidin-3-yl-)chromen-4-on.
  8. Verwendung einer Verbindung der allgemeinen Formel (Ic) nach irgendeinem der Ansprüche 1 bis 7 oder eines pharmazeutisch annehmbaren Salzes davon für die Herstellung eines Arzneimittels für die Inhibierung von Cyclin-abhängigen Kinasen.
  9. Verwendung einer Verbindung der allgemeinen Formel (Ic) nach irgendeinem der Ansprüche 1 bis 7 oder eines pharmazeutisch annehmbaren Salzes davon für die Herstellung eines Arzneimittels für die Behandlung oder Vorbeugung von proliferativen Störungen.
  10. Verwendung einer Verbindung der allgemeinen Formel (Ic) nach irgendeinem der Ansprüche 1 bis 7 oder eines pharmazeutisch annehmbaren Salzes davon für die Herstellung eines Arzneimittels für die Behandlung oder Vorbeugung von Störungen, die verbunden sind mit einer Dedifferenzierung einer differenzierten Zell-Population in einem Säuger.
  11. Verwendung einer Verbindung der allgemeinen Formel (Ic) nach irgendeinem der Ansprüche 1 bis 7 oder eines pharmazeutisch annehmbaren Salzes davon für die Herstellung eines Arzneimittels für die Behandlung oder Vorbeugung von Krebs.
  12. Verwendung einer Verbindung der allgemeinen Formel (Ic) nach irgendeinem der Ansprüche 1 bis 7 oder eines pharmazeutisch annehmbaren Salzes davon für die Herstellung eines Arzneimittels für die Vorbeugung oder Behandlung von degenerativen Störungen, mykotischen Infektionen, viralen Infektionen, parasitären Krankheiten, dermatologischen Störungen oder nephrologischen Störungen.
  13. Verwendung einer Verbindung der allgemeinen Formel (Ic) nach irgendeinem der Ansprüche 1 bis 7 als Insektizid oder in Landwirtschafts-Anwendungen.
  14. Pharmazeutische Zubereitung, umfassend eine therapeutisch wirksame Menge wenigstens einer Verbindung der allgemeinen Formel (Ic) gemäß irgendeinem der Ansprüche 1 bis 7 oder ein pharmazeutisch annehmbares Salz davon und einen pharmazeutisch annehmbaren Träger.
  15. Pharmazeutische Zubereitung, umfassend eine therapeutisch wirksame Menge wenigstens einer Verbindung der allgemeinen Formel (Ic) gemäß irgendeinem der Ansprüche 1 bis 7 oder ein pharmazeutisch annehmbares Salz davon und wenigstens eine weitere pharmazeutisch aktive Verbindung, zusammen mit einem pharmazeutisch annehmbaren Träger.
  16. Verwendung einer Verbindung der allgemeinen Formel (Ic) nach irgendeinem der Ansprüche 1 bis 7 oder eines pharmazeutisch annehmbaren Salzes davon für die Herstellung eines Arzneimittels für die Behandlung oder Vorbeugung von Störungen, die mit übermäßiger Zell-Proliferation verbunden sind, wobei das Arzneimittel verabreicht wird entweder aufeinander folgend oder gleichzeitig mit wenigstens einer anderen pharmazeutisch aktiven Verbindung.
  17. Verfahren für die Herstellung einer Verbindung der allgemeinen Formel (Ic) gemäß irgendeinem der Ansprüche 1 bis 7 oder eines pharmazeutisch annehmbaren Salzes davon, wobei das Verfahren umfasst entweder
    (a) Umsetzen eines Benzopyranons der Formel (II):
    Figure imgb0050
     worin R1, R2, R3, R4, R5 und Z die Bedeutung haben, die in irgendeinem der Ansprüche 1 bis 6 definiert ist, und P eine funktionelle Gruppe ist, mit einer Verbindung der Formel (III),
    Figure imgb0051
     worin A substituiert ist durch R6 und R7 und A, R6 und R7 die Bedeutung aufweisen, die in irgendeinem der Ansprüche 1 bis 6 definiert ist, mit der Ausnahme, dass A verschieden ist von einem 5-gliedrigen Ring der allgemeinen Struktur (ii) und (v) gemäß der obigen Definition, worin X ein Stickstoff-Atom ist; Q eine funktionelle Gruppe ist, die an ein gesättigtes oder ungesättigtes Kohlenstoff-Atom in dem Ring A gebunden ist, und
    (i) worin Q gebunden ist an ein ungesättigtes Kohlenstoff-Atom, Durchführen der Reaktion in Gegenwart eines Metall-Katalysators, einer organischen oder anorganischen Base und eines organischen oder anorganischen Lösungsmittels, wobei eine Kohlenstoff-Kohlenstoff-Bindung gebildet wird zwischen den jeweiligen Kohlenstoff-Atomen, an die P und Q gebunden sind, gefolgt von einer Behandlung mit einem reduzierenden Mittel unter Reduzieren irgendeiner Doppelbindung zwischen Gliedern an den Positionen 1 und 2 oder 1 und 5 eines 5-gliedrigen Rings A unter Bildung einer Verbindung der Formel (Ic); und
    (ii) worin Q gebunden ist an ein gesättigtes Kohlenstoff-Atom, Durchführen der Reaktion in Gegenwart eines geeigneten Liganden oder Katalysators und einer Abgangs-Gruppe, wobei eine Kohlenstoff-Kohlenstoff-Bindung gebildet wird zwischen den jeweiligen Kohlenstoff-Atomen, an die P und Q gebunden sind, unter Bildung einer Verbindung der Formel (Ic), und
    wenn angemessen, Umwandeln der resultierenden Verbindung in ein pharmazeutisch annehmbares Salz; oder
    (b) Umsetzen eines Benzopyranons der Formel (II):
    Figure imgb0052
     worin R1, R2, R3, R4, R5 und Z die Bedeutung haben, die in irgendeinem der Ansprüche 1 bis 6 definiert ist, und P eine funktionelle Gruppe ist, mit einer Verbindung der Formel (IIIA),
    Figure imgb0053
     worin X2 und R6 die Bedeutung aufweisen, die in irgendeinem der Ansprüche 1 bis 6 definiert ist, in Gegenwart eines Metall-Katalysators, einer organischen oder anorganischen Base und eines organischen oder anorganisches Lösungsmittels unter Bildung einer Stickstoff-Kohlenstoff-Bindung zwischen dem Kohlenstoff der Verbindung der Formel (II), an den P gebunden ist, und dem Stickstoff der Verbindung der Formel (IIIA), und - soweit erforderlich - Umwandeln der resultierenden Verbindung der Formel (Ic) in ein pharmazeutisch annehmbares Salz.
  18. Verfahren zur Herstellung einer Verbindung der allgemeinen Formel (Ic) gemäß irgendeinem der Ansprüche 1 bis 7 oder eines pharmazeutisch annehmbaren Salzes davon, worin Z ein Sauerstoff-Atom ist, R7 Wasserstoff ist, R1, R2, R3, R4, R5, R6 und A die Bedeutung haben, die in irgendeinem der Ansprüche 1 bis 6 definiert ist, wobei das Verfahren umfasst: ein Umsetzen einer Verbindung der allgemeinen Formel (XA):
    Figure imgb0054
     worin R1, R2, R3, R4, R5, R6, R7 und A wie oben definiert sind, mit einer organischen oder anorganischen Base, ein anschließendes Zugeben einer Säure, die in der Lage ist, eine Zyklisierung zu bewirken, zu der Reaktionsmischung, anschließendem Zusetzen einer organischen oder anorganischen Base und - sofern angemessen - Umwandeln der Verbindung der Formel (Ic) in ein pharmazeutisch annehmbares Salz, oder ein Umsetzen einer Verbindung der Formel (XIIA):
    Figure imgb0055
     worin R1, R2, R3, R4, R5, R6, R7 und A wie oben definiert sind, mit einer Säure, die in der Lage ist, eine Zyklisierung zu bewirken, gefolgt von einem Zusetzen einer organischen oder anorganischen Base zu der Reaktionsmischung und - sofern angemessen - ein Umwandeln der Verbindung der Formel (Ic) in ein pharmazeutisch annehmbares Salz.
  19. Verfahren nach Anspruch 18, worin die Verbindung von Formel (XIIA) erhalten wird durch Umsetzen einer Verbindung der Formel (XIA)
    Figure imgb0056
     worin R1, R2, R3, R4, R5, R6,R7 und A wie oben definiert sind, mit einem Carbonsäureester, einem Säurehalogenid oder einem aktivierten Ester in Gegenwart einer organischen oder anorganischen Base in einem organischen oder anorganischen Lösungsmittel.
  20. Verfahren nach Anspruch 18 oder Anspruch 19, worin A gewählt ist aus:
    (a)
    Figure imgb0057
    (b)
    Figure imgb0058
     und
    (c)
    Figure imgb0059
    worin R11 und R13 wie oben definiert sind.
  21. Verfahren nach Anspruch 20, worin R11 Wasserstoff ist und/oder R13 Methyl ist.
  22. Verfahren zur Herstellung einer Verbindung von Formel (XIIIA) oder eines pharmazeutisch annehmbaren Salzes davon:
    Figure imgb0060
     worin R1, R2, R3, R4, R5, R13 und Z so sind, wie dies in irgendeinem der Ansprüche 1 bis 6 definiert ist, umfassend ein Umsetzen einer Verbindung der Formel (VIIA)
    Figure imgb0061
     worin R1, R2, R3, R4, R5, R13 und Z so sind, wie dies in irgendeinem der Ansprüche 1 bis 6 definiert ist, mit einem Reagenz, das geeignet ist, ein Ersetzen der -OH-Gruppe an dem Piperidino-Ring durch eine Abgangsgruppe zu bewirken, in Gegenwart einer organischen oder anorganischen Base, gefolgt vom Zugeben einer geeigneten organischen Base in Gegenwart eines geeigneten organischen Lösungsmittels unter Bewirken einer Kontraktion des Piperidino-Rings und - sofern angemessen - Umwandeln der resultierenden Verbindung der Formel (XIIIA) in ein pharmazeutisch annehmbares Salz.
  23. Verfahren für die Herstellung einer Verbindung der Formel (XXXVII) oder eines pharmazeutisch annehmbaren Salzes davon:
    Figure imgb0062
     worin R1, R2, R3, R4, R5 und Z so sind, wie dies in irgendeinem der Ansprüche 1 bis 6 definiert ist, wobei das Verfahren umfasst ein Umsetzen einer Verbindung der Formel (XXXVI)
    Figure imgb0063
     worin R1, R2, R3, R4, R5 und Z so sind, wie dies in irgendeinem der Ansprüche 1 bis 6 definiert ist, mit einem reduzierenden Mittel, das in der Lage ist, die Ester-Gruppe -C(O)OEt an den Imidazolyl-Ring zu der Gruppe -CH2OH zu reduzieren, und - sofern angemessen - Umwandeln der resultierenden Verbindung der Formel (XXXVII) in ein pharmazeutisch annehmbares Salz.
  24. Verfahren nach Anspruch 23, worin die Verbindung der Formel (XXXVI) hergestellt wird durch Umsetzen einer Verbindung der Formel (XXXV):
    Figure imgb0064
     worin R1, R2, R3, R4, R5 und Z so sind, wie dies in irgendeinem der Ansprüche 1 bis 6 definiert ist, mit einem Isocyanid in Gegenwart einer anorganischen Base in einem organischen Lösungsmittel.
  25. Verfahren zur Herstellung einer Verbindung der allgemeinen Formel (XIII):
    Figure imgb0065
     worin R1, R2, R3, R4, R5 und R13 so sind, wie dies in irgendeinem der Ansprüche 1 bis 6 definiert ist, umfassend ein Umsetzen einer racemischen Verbindung der Formel (VIII):
    Figure imgb0066
     worin R3, R4, R5 und R13 so sind, wie dies in irgendeinem der Ansprüche 1 bis 6 definiert ist, mit einem chiralen Hilfsstoff in Gegenwart eines Lösungsmittels unter Bildung eines diastereomeren Salzes der Verbindung der Formel (VIII), Auskristallisieren des benötigten diastereomeren Salzes und anschließendes Behandeln mit einer Base unter Erhalt des gewünschten Enantiomers der Verbindung der Formel (VIII), Behandeln der Verbindung der Formel (VIII) mit einem acylierenden Mittel oder einer aktivierten Form einer Säure in Gegenwart eines Lewis-Säure-Katalysators unter Erhalt der acylierten Verbindung der Formel (IX):
    Figure imgb0067
     worin R2, R3, R4, R5 und R13 so sind, wie dies in irgendeinem der Ansprüche 1 bis 6 definiert ist, Behandeln der Verbindung der Formel (IX) mit entweder
    (a) einem Säurechlorid des Typs R1COCl, einem Anhydrid des Typs (R1CO)2O oder einem Ester des Typs R1COOCH3, worin R1 wie definiert ist,
    (b) einer Säure des Typs R1COOH, worin R1 wie definiert ist, und Phosphoroxychlorid in Gegenwart eines Säure abfangenden Mittels unter Erhalt eines Säurechlorids in situ unter neutralen Bedingungen, oder
    (c) einer Kombination von R1COOH, worin R1 wie definiert ist, und Polyphosphorsäure,
    unter Bildung der Verbindung der Formel (X)
    Figure imgb0068
     worin R1, R2, R3, R4, R5 und R13 so sind, wie dies in irgendeinem der Ansprüche 1 bis 6 definiert ist, Behandeln der Verbindung der Formel (X) mit einer Base, gefolgt von einem Behandeln mit einer starken Säure, die in der Lage ist, eine Zyklisierung zu bewirken und anschließend mit einer milden Base unter Bildung der gegenständlichen Verbindung der Formel (XIII), und - gegebenenfalls - Umwandeln der gegenständlichen Verbindung in ein pharmazeutisch annehmbares Salz;
    alternativ dazu Unterziehen der Verbindung der obigen Formel (IX) einer Esterhydrolyse durch Behandeln mit einer Base in wässrigem Ethanol oder Methanol unter Bildung einer Verbindung der Formel (XI)
    Figure imgb0069
     worin R2, R3, R4, R5 und R13 so sind, wie dies in irgendeinem der Ansprüche 1 bis 6 definiert ist,
    Behandeln der Verbindung der Formel (XI) mit einem Carbonsäureester, einem Säurechlorid oder einem aktivierten Ester in Gegenwart einer Base in einem Lösungsmittel unter Bildung einer Verbindung der Formel (XII).
    Figure imgb0070
     worin R1, R2, R3, R4, R5 und R13 so sind, wie dies in irgendeinem der Ansprüche 1 bis 6 definiert ist, und Behandeln der Verbindung der Formel (XII) mit einer Base, gefolgt vom Bewirken einer Zyklisierung durch Behandlung mit einer starken Säure und anschießendes Behandeln mit einer milden Base unter Bildung der gegenständlichen Verbindung der Formel (XIII) und - gegebenenfalls - Umwandeln der gegenständlichen Verbindung in ein pharmazeutisch annehmbares Salz.
EP03753911A 2002-07-08 2003-07-07 Flavon derivate als inhibitoren von cyclin-abhängigen kinasen Expired - Lifetime EP1556375B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
INMU06162002 2002-07-08
IN616MU2002 2002-07-08
PCT/IN2003/000234 WO2004004632A2 (en) 2002-07-08 2003-07-07 Flavone derivatives as inhibitors of cyclin-dependent kinases

Publications (2)

Publication Number Publication Date
EP1556375A2 EP1556375A2 (de) 2005-07-27
EP1556375B1 true EP1556375B1 (de) 2008-06-25

Family

ID=30012269

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03753911A Expired - Lifetime EP1556375B1 (de) 2002-07-08 2003-07-07 Flavon derivate als inhibitoren von cyclin-abhängigen kinasen

Country Status (20)

Country Link
EP (1) EP1556375B1 (de)
JP (1) JP4860148B2 (de)
KR (1) KR100991920B1 (de)
CN (1) CN1668613B (de)
AR (1) AR041184A1 (de)
AT (1) ATE399162T1 (de)
AU (1) AU2003272070B2 (de)
BR (1) BR0312633A (de)
CA (1) CA2492130C (de)
DE (1) DE60321808D1 (de)
DK (1) DK1556375T3 (de)
ES (1) ES2309338T3 (de)
IL (1) IL166153A (de)
MX (1) MXPA05000388A (de)
NZ (1) NZ537518A (de)
PT (1) PT1556375E (de)
RU (1) RU2334746C2 (de)
TW (1) TWI331034B (de)
WO (1) WO2004004632A2 (de)
ZA (1) ZA200500138B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7915301B2 (en) 2002-07-08 2011-03-29 Piramal Life Science Limited Inhibitors of cyclin dependent kinases and their use
CA2655789C (en) * 2006-06-21 2014-04-01 Piramal Life Sciences Limited Enantiomerically pure flavone derivatives for the treatment of poliferative disorders and processes for their preparation
BRPI0621851A2 (pt) 2006-07-07 2013-01-29 Piramal Life Sciences Ltd sÍntese enantiosseletiva de pirrolidinas substituÍdas com flavonas, e intermediÁrios das mesmas
JP5688288B2 (ja) * 2007-05-15 2015-03-25 ピラマル エンタープライジーズ リミテッド がんの処置のための相乗的な医薬の組合せ
CN101333205A (zh) * 2008-07-10 2008-12-31 大连理工大学 周期素依赖蛋白激酶抑制剂黄芩素哌嗪衍生物及其制法
TWI461194B (zh) 2009-05-05 2014-11-21 Piramal Entpr Ltd 吡咯啶取代黃酮作為輻射致敏劑
EP2429292B1 (de) * 2009-05-08 2019-04-03 Georgia State University Research Foundation Verbindungen und zusammensetzungen mit cdk-hemmern und deren verwendung zur behandlung von krebs
US7928067B2 (en) 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
EP2538941A1 (de) * 2010-02-26 2013-01-02 Piramal Enterprises Limited Pyrrolidinsubstituierte flavone zur behandlung von entzündungserkrankungen
KR20140020840A (ko) 2010-11-18 2014-02-19 이쉐믹스 엘엘씨 허혈성 손상을 치료하기 위한 리포일 화합물 및 이의 용도
WO2012069972A1 (en) 2010-11-19 2012-05-31 Piramal Life Sciences Limited A pharmaceutical combination for the treatment of breast cancer
WO2012066508A1 (en) * 2010-11-19 2012-05-24 Piramal Life Sciences Limited Pharmaceutical combination of paclitaxel and a cdk inhibitor
WO2012123889A1 (en) 2011-03-14 2012-09-20 Piramal Healthcare Limited A synergistic pharmaceutical combination for the treatment of pancreatic cancer
US8530470B2 (en) * 2011-04-13 2013-09-10 Astrazeneca Ab Chromenone derivatives
TW201300105A (zh) * 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
BR112013033311A2 (pt) 2011-06-24 2017-08-22 Piramal Entpr Ltd Compostos para o tratamento de cânceres associados com papilomavírus humano
IN2014MN01546A (de) 2012-01-13 2015-05-08 Piramal Entpr Ltd
WO2014049515A1 (en) * 2012-09-25 2014-04-03 Piramal Enterprises Limited Pyrrolidine substituted flavones for treatment of renal cystic diseases
WO2015004636A1 (en) * 2013-07-12 2015-01-15 Piramal Enterprises Limited A pharmaceutical combination for the treatment of melanoma
EP3148532B1 (de) 2014-05-28 2021-03-03 Piramal Enterprises Limited Pharmazeutische kombination, die einen cdk-inhibitor und einen thioredoxin-reduktase-inhibitor enthält, zur behandlung von krebs
US20180180994A1 (en) * 2015-06-23 2018-06-28 Covestro Deutschland Ag Substituted triazines
JP7114478B2 (ja) 2016-03-28 2022-08-08 プレサージュ バイオサイエンシズ，インコーポレイテッド 癌の治療のための配合剤
CA3040815C (en) 2016-10-20 2021-07-20 Steven Martin Evans Anti-proliferative agents for treating pah
DK3615023T3 (da) 2017-04-25 2023-09-25 Ischemix Llc Lipoyl-glu-ala til behandlingen af neurodegenerativ skade forårsaget af traumatisk hjerneskade
CN107573270B (zh) * 2017-09-29 2019-11-29 河南师范大学 一种α-甲酰基吡咯烷类化合物的合成方法
EP3866929A1 (de) 2018-10-19 2021-08-25 F. Hoffmann-La Roche AG Chromen-4-on-derivate zur behandlung und prophylaxe von hepatitis-b-viruserkranungen
CN110028475B (zh) * 2019-05-13 2022-07-01 中国药科大学 基于苯并吡喃结构的新型cdk9抑制剂、其制备方法及应用
CA3163105A1 (en) 2019-11-28 2021-06-03 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
AR121719A1 (es) 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
CR20230517A (es) 2021-05-03 2023-11-28 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
US11878970B2 (en) 2021-05-27 2024-01-23 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease
CN113549044B (zh) * 2021-07-23 2024-01-23 中国药科大学 8-氮杂环取代色酮类衍生物及其制备方法与制药用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3836676A1 (de) * 1988-10-28 1990-05-03 Hoechst Ag Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US5849733A (en) * 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
EP1280789A1 (de) * 2000-05-03 2003-02-05 LG Life Sciences Ltd. Cdk-inhibitoren mit 3-hydroxychromen-4-on-struktur

Also Published As

Publication number Publication date
KR100991920B1 (ko) 2010-11-04
IL166153A (en) 2009-11-18
CN1668613B (zh) 2012-07-04
NZ537518A (en) 2008-02-29
CA2492130C (en) 2011-09-06
ATE399162T1 (de) 2008-07-15
JP4860148B2 (ja) 2012-01-25
MXPA05000388A (es) 2005-09-30
TWI331034B (en) 2010-10-01
EP1556375A2 (de) 2005-07-27
WO2004004632A3 (en) 2004-09-16
PT1556375E (pt) 2008-10-03
WO2004004632A8 (en) 2005-03-24
AU2003272070A1 (en) 2004-01-23
TW200406202A (en) 2004-05-01
WO2004004632A2 (en) 2004-01-15
RU2005102939A (ru) 2005-09-10
DE60321808D1 (de) 2008-08-07
KR20050017110A (ko) 2005-02-21
AR041184A1 (es) 2005-05-04
JP2006502109A (ja) 2006-01-19
DK1556375T3 (da) 2008-11-03
IL166153A0 (en) 2006-01-15
BR0312633A (pt) 2005-07-19
ZA200500138B (en) 2006-02-22
CA2492130A1 (en) 2004-01-15
AU2003272070B2 (en) 2009-02-26
CN1668613A (zh) 2005-09-14
RU2334746C2 (ru) 2008-09-27
ES2309338T3 (es) 2008-12-16

Similar Documents

Publication Publication Date Title
EP1556375B1 (de) Flavon derivate als inhibitoren von cyclin-abhängigen kinasen
US7884127B2 (en) Inhibitors of cyclin dependent kinases and their use
US8304449B2 (en) Inhibitors of cyclin dependent kinases and their use
JP5498782B2 (ja) 増殖性疾患治療用のエナンチオマー的に純粋なフラボン誘導体の調製方法
EP1119548B1 (de) 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)
JP7372686B2 (ja) Ｔｒｋ阻害剤としてのヘテロ環化合物
US7271193B2 (en) Inhibitors of cyclin-dependent kinases and their use
EP2880023A1 (de) Griseofulvinderivate
EP0558950A1 (de) 3-Aryl-Glycidsäureester und Verfahren zu ihrer Herstellung
RU2418786C2 (ru) Энантиомерно чистые производные флавона для лечения пролиферативных нарушений и способы их получения

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050127

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20060613

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KAMBLE, SHRIKANT, GANGADHAR

Inventor name: JOSHI, KALPANA, SANJAY

Inventor name: RATHOS, MAGGIE, JOYCE,201/A, NIRMAL CO-OP HSG SO.

Inventor name: KULKARNI, SANJEEV, ANANT

Inventor name: JOSHI, RAJENDRAKUMAR, DINANATH

Inventor name: LAL, BANSI

Inventor name: MASCARENHAS, MALCOLM

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 60321808

Country of ref document: DE

Date of ref document: 20080807

Kind code of ref document: P

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20080923

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20080402481

Country of ref document: GR

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: STUDIO RAPISARDI S.A.

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080625

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080625

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2309338

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080625

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080625

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080625

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080731

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20090201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080625

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080925

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20090326

NLXE Nl: other communications concerning ep-patents (part 3 heading xe)

Free format text: A REQUEST FOR RESTORATION TO THE PRIOR STATE (ARTICLE 23 OF THE PATENTS ACT 1995) HAS BEEN FILED ON 20090714

REG Reference to a national code

Ref country code: NL

Ref legal event code: RD2A

Effective date: 20100421

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081226

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080625

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080625

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: PIRAMAL HEALTHCARE LIMITED

Free format text: NICHOLAS PIRAMAL INDIA LIMITED#100 CENTREPOINT, DR. AMBEDKAR ROAD, PAREL#MUMBAI 400 012, MAHARASHTRA (IN) -TRANSFER TO- PIRAMAL HEALTHCARE LIMITED#PIRAMAL TOWER GANPATRAO KADAM PARK LOWER PAREL#MUMBAI 400 013 (IN)

Ref country code: CH

Ref legal event code: PUE

Owner name: PIRAMAL LIFE SCIENCES LIMITED

Free format text: PIRAMAL HEALTHCARE LIMITED#PIRAMAL TOWER GANPATRAO KADAM PARK LOWER PAREL#MUMBAI 400 013 (IN) -TRANSFER TO- PIRAMAL LIFE SCIENCES LIMITED#PIRAMAL TOWER GANPATRAO KADAM MARG LOWER PAREL#MUMBAI 400 013 (IN)

REG Reference to a national code

Ref country code: PT

Ref legal event code: PC4A

Owner name: PIRAMAL LIFE SCIENCES LIMITED, IN

Effective date: 20100923

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Ref country code: FR

Ref legal event code: CD

Ref country code: FR

Ref legal event code: CA

REG Reference to a national code

Ref country code: NL

Ref legal event code: TD

Effective date: 20110818

Ref country code: NL

Ref legal event code: SD

Effective date: 20110818

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Owner name: PIRAMAL ENTERPRISES LIMITED, IN

Effective date: 20121024

Ref country code: FR

Ref legal event code: CD

Owner name: PIRAMAL ENTERPRISES LIMITED, IN

Effective date: 20121024

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20121122 AND 20121128

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 60321808

Country of ref document: DE

Owner name: PIRAMAL ENTERPRISES LTD., IN

Free format text: FORMER OWNER: PIRAMAL LIVE SCIENCE LTD., MAHARASHTRA, IN

Effective date: 20121031

Ref country code: DE

Ref legal event code: R082

Ref document number: 60321808

Country of ref document: DE

Representative=s name: MUELLER SCHUPFNER & PARTNER PATENT- UND RECHTS, DE

Effective date: 20121031

Ref country code: DE

Ref legal event code: R081

Ref document number: 60321808

Country of ref document: DE

Owner name: PIRAMAL ENTERPRISES LTD., MUMBAI, IN

Free format text: FORMER OWNER: PIRAMAL LIVE SCIENCE LTD., MAHARASHTRA, IN

Effective date: 20121031

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: PIRAMAL ENTERPRISES LIMITED

Effective date: 20130917

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: NEW ADDRESS: VIA MAGATTI 1, 6901 LUGANO (CH)

REG Reference to a national code

Ref country code: PT

Ref legal event code: PC4A

Owner name: PIRAMAL HEALTHCARE LIMITED, IN

Effective date: 20140929

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: PIRAMAL ENTERPRISES LIMITED, IN

Free format text: FORMER OWNER: PIRAMAL LIFE SCIENCES LIMITED, IN

REG Reference to a national code

Ref country code: NL

Ref legal event code: TD

Effective date: 20150224

Ref country code: NL

Ref legal event code: SD

Effective date: 20150224

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20150626

Year of fee payment: 13

Ref country code: ES

Payment date: 20150629

Year of fee payment: 13

Ref country code: LU

Payment date: 20150630

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20150623

Year of fee payment: 13

Ref country code: GR

Payment date: 20150625

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20150708

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20150728

Year of fee payment: 13

Ref country code: CH

Payment date: 20150715

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20150729

Year of fee payment: 13

Ref country code: SE

Payment date: 20150727

Year of fee payment: 13

Ref country code: BE

Payment date: 20150629

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20150729

Year of fee payment: 13

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160731

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20170131

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20160801

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 399162

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160707

REG Reference to a national code

Ref country code: GR

Ref legal event code: ML

Ref document number: 20080402481

Country of ref document: GR

Effective date: 20170207

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160731

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160801

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170207

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160731

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160708

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160707

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170109

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160707

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160707

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160707

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160708

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20181130

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20220727

Year of fee payment: 20

Ref country code: DE

Payment date: 20220727

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20220725

Year of fee payment: 20

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230524

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 60321808

Country of ref document: DE

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20230706

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20230706